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ABSTRACT 
 
Breast cancer continues to be the leading cause of cancer-related 
death in women worldwide. In this dissertation, natural compounds with 
anti-breast cancer activities were identified. We investigated the effect of 
Salinomycin, a potassium ionophore isolated from Streptomyces albus, on 
the survival of three human breast cancer cell lines MCF-7, T47D and 
MDA-MB-231. High concentrations of Salinomycin induced a G2 arrest, 
down regulation of survivin and triggered apoptosis. Interestingly, 
treatments with low concentrations of Salinomycin induced a transient G1 
arrest at an earlier time and G2 arrest and senescence, associated with 
enlarged cell morphology, at a later time. There was also an upregulation 
of p21 protein, an increase in Histone H3 and H4 hyperacetylation and 
expression of SA-β-Gal activity. Furthermore, it was found that 
Salinomycin was able to potentiate the killing of the MCF-7 and MDA-MB-
231 cells, by the chemotherapeutic agents, 4-Hydroxytamoxifen and 
frondoside A, We also investigated the effect of Origanum majorana, a 
culinary herb, ethanolic extract (OME) on the survival, migration, invasion 
and tumor growth of the highly proliferative and invasive triple-negative 
p53 mutant breast cancer cell line MDA-MB-231. We found that OME 
inhibited the viability of MDA-MB-231 breast cancer cells both in vitro and 
in vivo. OME was found to elicit anti-breast cancer activity by inducing 
mitotic arrest, DNA damage and triggering the extrinsic apoptotic pathway.  
Moreover, OME was found to induce down regulation of survivin, 
an important therapeutic target against breast cancer.  
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OME was also found to inhibit cell migration and invasion, two major 
events required for tumor metastasis. Our data are the first to link 
senescence and histone modifications to Salinomycin which provides a 
new insight to better understand the mechanism of action of Salinomycin, 
at least in breast cancer cells. Moreover, our findings provide strong 
evidence that O. majorana may be a promising chemopreventive and 
therapeutic candidate against cancer especially for highly invasive triple 
negative p53 mutant breast cancer; thus validating its use in alternative 
medicine. 
 
Keywords: Breast Cancer, Apoptosis, DNA Damage, Histone 
Hyperacetylation, p21, Salinomycin, Origanum majorana, Senescence-
Associated Beta Galactosidase (SA-β-Gal), Mitotic Arrest.   
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 الملخص
لايزال سرطان الثدي السبب الرئيسي للوفيات المرتبطة بالسرطان بين النساء في جميع أنحاء 
في هذه  في هذه الأطروحة ، تم دراسة تأثير نشاط بعض المركبات الطبيعية  المضادة لسرطان الثدي.العالم . 
 السلالةالممعزول من  وحامل لأيون البوتاسيوم  مركبتم دراسة تأثير السالينوميسين ، الأطروحة 
 FCMلسرطان الثدي:  الخلايا البشرية أنواعمن ، على حيوية و تكاثر ثلاثة  subla secumotpertS
التركيزات العالية من السالينوميسين أدى إلى  أظهرت نتائج البحث أن. 132 -BM -ADMو  D74T، 7-
  تحفيز و تسبب في nivivrus،  وانخفاض تنظيم بروتين ال  2Gوقف دورة حياة الخلايا عند مرحلة ال 
ومن المثير للاهتمام أن المعاملة مع تركيزات منخفضة من السالينوميسين نتج عنه توقف موت الخلايا المبرمج. 
و وقف دورة حياة الخلايا في مرحلة  ساعة من المعالجة 24في خلال   1Gمرحلة ال دورة حياة الخلايا عند
 زيادة في تنظيمساعة من المعالجة ،  42و الشيخوخة المرتبطة بكبر في حجم الخلايا في خلال  2Gال 
) و زيادة في نشاط تعبير من noitalytecarepyh( 4H 3H، وزيادة في هيستون  12Pالبروتين 
السالينوميسين كان قادرا على تحفيز قتل خلايا الثدي السرطانية  علاوة على ذلك ، وجدنا أن. -laG-β -AS
-4 ، عند الإستخدام مع أدوية العلاج الكيميائي، 132 -BM -ADMو  7 -FCM
في الجزء الثاني من الأاطروحة تم دراسة  ، على التوالي.A edisodnorfو  nefixomatyxordyH
و هي نبتة منتشرة في كافة أنحاء  ،  )anarojam munagirO( نبتة البرقوش وراقأمستخلص  تأثير
، على حيوية, تكاثر, هجرة والغزو و نمو الورم من العالم و تستخدم في الطهي و كدواء عشبي تقليدي 
أن نتائج البحث  أظهرت.  )132 -BM -ADM( الثلاثي السلبي واسع االإنتشار/ خلايا سرطان الثدي
على  132 -BM -ADMتحول دون جدوى على تكاثر و حيوية خلايا الثدي السرطانية  نبتة البردقوش 
أظهرت النتائج المخبرية أن  حد سواء في المختبر و نمو الورم في الجسم الحي (الحيوانات المخبرية). 
الخلايا الإنقسامية ، قوم بنشاطها المضاد لسرطان الثدي عن طريق حفز وقف دورة حياة ت نبتة البردقوش
التسبب في الموت المبرمج للخلايا عن طريق المسار الخارجي  ) و ANDتحفيز تلف الحمض النووي (
تحث على تقليل من مستخلص هذه النبة علاوة على ذلك، أظهرت النتائج أيضا أن للموت المبرمج للخلايا. 
كذلك وجدنا ان هذا المستخلص فعال في ، هدفا علاجيا هاما ضد سرطان الثدي.  nivivrusبروتين ال تنظيم 
منع هجرة الخلايا السرطانية و غزوها لأماكن أخرى في الجسم ، اثنين من الأحداث الكبرى الأساسية لل ورم 
 .الخبيث
 iiv
 
ائية كيميائية واعدة قد تكون وق نبتة البرقوشتقدم النتائج التي توصلنا إليها أدلة قوية على أن مستخلص  
 35pو مرشح العلاجية ضد السرطان وخاصة بالنسبة لخط خلاياسرطان الثدي ثلاثي السلبية متحولة البروتين 
وبالتالي التحقق من صحة استخدامه الطبية التكميلية والبديلة . الأهم من ذلك، البيانات الغازية للغاية ؛ 
لسالينوميسين الشيخوخة و  التغير في تعبير الهيستون و الذي المتوفرة لدينا هي الأولى التي تربط بين ا
 .يوفر رؤية جديدة لفهم أفضل لآلية عمل السالينوميسين ، على الأقل على خلايا سرطان الثدي
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 1 
CHAPTER 1: INTRODUCTION 
1.1  Breast Cancer 
Breast cancer is the leading cause of cancer-related death in 
women worldwide. Approximately one-third of all women with breast 
cancer develop metastasis and ultimately die as a result of the effects of 
the disease. The American cancer society estimated nearly 232,670 new 
cases and about 40,000 deaths estimated due to breast cancer in women 
in 2014 [1]. According to the UAE Ministry of Health, breast cancer is the 
most common malignancy diagnosed among women in the UAE. Women 
in the UAE tend to develop breast cancer at least a decade earlier than 
their counterparts in the West, according to a study [210]. Remarkable 
progress has been made in the treatment of breast cancer over the years 
with hormonal therapy for estrogen receptors and/or progesterone 
receptors positive tumors, as well as other therapies. However, despite 
these advances, breast cancer remains a frequent cause of death in 
women.  
1.2 Tripe Negative Breast Cancer 
Triple-Negative Breast Cancer (TNBC) is a subtype of breast 
cancer characterized by tumors that do not express estrogen receptors 
(ER), progesterone receptors (PR), or human epidermal growth factor 
membrane receptors (HER-2). It comprises about 15% of all breast cancer 
cases [2]. It is characterized by its unique molecular profile, aggressive 
behavior, and distinct pattern of metastasis, including lung, liver and brain 
metastasis [3]. Epidemiological studies showed a high prevalence of triple 
negative breast cancer among younger women and those of African 
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descent. TNBC has a poor prognosis and relapse quickly compared with 
other subtypes of breast cancer that are positive for hormonal receptors or 
HER2 membrane receptors [4].  
Gene-expression profiling approaches demonstrated that TNBC is 
a heterogeneous group of diseases composed of different, molecularly 
distinct subtypes [4, 5]. Although not synonymous, the majority of TNBC 
share morphological and genetic abnormalities with basal-like breast 
cancer, a subgroup of breast cancer defined by gene-expression profiling, 
where TNBC constitutes approximately 80% of all basal-like tumors. 
However, several studies have shown that TNBC includes tumors with a 
non-basal expression profile and, in particular, normal-breast, the multiple 
markers negative, as well as the recently identified claudin-negative 
subtype [4, 5]. TNBC also has molecular features that overlap with breast 
cancer, BRCA-1 germline mutation, and is also associated with p53 
mutations [2, 6].  
TNBC represents an important clinical challenge because these 
types of cancer do not respond to hormonal therapy or other available 
treatments. Despite advances in the treatment of hormone receptors (HR) 
and human epidermal growth factor receptors (HER2)-positive breast 
cancers, the prospects for women with TNBC remains poor and 
conventional chemotherapy remains the main treatment of TNBC even 
though TNBC becomes highly resistant [7]. Preclinical and clinical studies 
have suggested several agents that are active in TNBC. These agents 
include DNA-damaging agents and poly (ADP-ribose) polymerase (PARP) 
inhibitors which are active in TNBC associated with BRCA1 dysfunction. 
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Anti-epidermal growth factor receptors (EGFR) antibodies and EGFR 
tyrosine kinase inhibitors are active in TNBC with EGFR gene 
amplification. Dasatinib is active in TNBC with activated Src tyrosine 
kinase and inhibitors of mammalian target of rapamycin (mTOR) are 
active in TNBC with loss of PTEN tumor suppressors. Anti-angiogenic 
therapies were shown to enhance antitumor activity of chemotherapeutic 
agents in hypervascular TNBC. To develop novel strategies against 
TNBC, it is essential to understand the pathways driving the aggressive 
behavior of these types of cancer [8-10].  
1.3. Cancer Metastasis 
Cancer metastasis starts in the primary tumor site when cancer 
cells start to invade and degrade the basement membrane and 
extracellular matrix (ECM) to get into the vascular or lymphatic circulation 
system. Loss of cell to cell adhesion, induces the disassembly of cancer 
cells from the primary tumor, disseminating to distant sites through blood 
vessels and lymphatics, and eventually they leave the circulation to 
establish metastasis in distant organs [11, 12]. E-cadherin, a cell–cell 
adhesion molecule, plays a major role in the establishment and 
maintenance of normal tissue architecture. It is expressed predominantly 
on the surface of normal epithelial cells. For cancer cells to become 
metastatic, they must decrease E-cadherin expression and break cell-cell 
adhesions and induce cell mobility triggering a transition from tumorigenic 
(epithelial) to migratory/invasive (mesenchymal) phenotype ending in 
tumor metastasis. Hence, the expression level of the epithelial cadherin 
(E-cadherin) has become an important indicator of these transitions [13, 
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14]. Therefore, searching for agents that could enhance E-cadherin 
expression is therapeutic aim in order to repress the metastatic potential 
of cancer cells.  
The adherence of tumor cells to endothelial cells is an essential 
step during cancer progression and metastasis. Several adhesive 
molecules, such as intracellular adhesion molecule-1 (ICAM-1), have 
been identified as being responsible for the endothelial adhesion of cancer 
cells [15]. While ICAM-1 expression was found at low basal levels in many 
cell types, including epithelial and endothelial cells [16], its expression as 
a soluble serum ICAM-1 were found to be high in metastatic breast cancer 
patients [16]. Therefore, agents that repress ICAM-1 expression in breast 
cancer cells, and subsequently block the interaction between cancer and 
endothelial cells, might be an important therapeutic target for repressing 
the metastatic potential of cancer cells. 
1.3.1. Tumor Cell Invasion in Cancer Metastasis 
Degradation of the extracellular matrix (ECM) surrounding the 
primary tumor is an essential step in tumorigenesis. This degradation is 
important for tissue remodeling and the induction of angiogenesis, and is 
mainly mediated by specific proteolytic enzyme systems mainly matrix 
metalloproteinase (MMPs) and urokinase plasminogen activator (uPA). 
Among MMPs, upregulation of MMP-2 and MMP-9 was shown to be 
associated with breast cancer metastasis and poor clinical outcomes [17]. 
Northern blot analysis revealed that the level of MMP-2 and MMP-9 
mRNA was higher in breast cancer tissues compared to normal breast 
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tissue [18]. In addition, higher MMP-9 protein concentration was detected 
in breast cancer tissue when compared to normal breast tissue [19]. 
Similarly, higher protease activity for MMP-2 and MMP-9 was detected by 
zymography in tumor tissues compared to normal tissues [20].   
  MMPs are directly activated by Serine Protease Plasmin, which is 
activated from its proenzyme form (plasminogen) by serine protease 
urokinase-type plasminogen activator (uPA) upon binding to cell surface 
receptors (uPAR). Overexpression of uPA has been found in many tumor 
types and is correlated to a poor prognosis. Moreover, binding of uPA to 
uPAR also induces signal transduction, allowing enhanced cell migration 
[17, 21, 22]. Therefore, regulating the expression of ECM degradation 
enzymes is another therapeutic target to control breast cancer.  
1.3.2. Angiogenesis in Cancer Metastasis 
Angiogenesis is a complex multistep process involving soluble 
factors, adhesion molecules, proteases and cytokines. The process of 
tumor angiogenesis starts when tumor cells secrete and activate 
angiogenic factors, thereby activating proteolytic enzymes. At this time, 
endothelial cells proliferate, migrate, and differentiate. 
Vascular endothelial growth factor (VEGF) is the most prominent 
mediator in tumor angiogenesis that is induced in breast cancer [23]. Up-
regulation of VEGF expression has been reported in a variety of malignant 
human cancers including breast, colon, and lung cancers. An in situ 
hybridization study of human breast samples showed high VEGF 
expression in tumor cells but not in the normal duct epithelium [24]. 
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Hence, VEGF might be a good target in the treatment of breast cancer 
patients. 
1.3.3. Nuclear Factor B (NFB) in Cancer Progression and 
Metastasis 
Nuclear Factor B (NFB), (a transcription factor), is a key player in 
cancer metastasis [11]. It has been shown that several genes involved in 
tumor metastasis are directly regulated by NFB. The frequent over-
expression of NFB in tumor cells suggests that selected tumor cells may 
acquire metastatic activity via aberrant expression of metastasis relevant 
genes during their progression. In fact, studies showed that MMP-2 and 
MMP-9 [25, 26], uPA [27, 28], uPAR [29] and ICAM-1 [30] are 
downstream targets of the NFB signaling pathway. NF-κB provides 
mechanistic links between inflammation and cancer, and moreover, 
regulates tumor angiogenesis and invasiveness, indicating that signaling 
pathways that mediate their activation provide attractive targets for new 
chemotherapeutic approaches [11]. 
1.4. Programmed Cell Death through Apoptosis 
Apoptosis, a major form of programmed cell death, is a defense 
mechanism and a tumor suppressor pathway essential for the 
development and maintenance of cellular homeostasis. When deregulated 
apoptosis leads to an uncontrolled proliferation of damaged cells. It also 
leads to resistance to chemo and radio therapy [31]. Apoptosis can be 
triggered by diverse cellular signals. These include intracellular signals 
produced in response to cellular stress, such as increased intracellular 
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Ca2+ concentration, DNA damage and high levels of reactive oxygen 
species (ROS). Extrinsic inducers of apoptosis include bacterial 
pathogens, toxins, nitric oxide, growth factors and hormones [32]. 
Apoptosis is regulated by a series of signaling cascades and occurs via 
two connected pathways. The extrinsic pathway is initiated by cell surface 
death receptor stimulation and activation of caspase-8, while the intrinsic 
pathway involves cytochrome c release from mitochondria and 
subsequent caspase-9 activation. Activated caspase-8 and-9 activate 
executioner caspases, including caspase-3, which in turn activate a 
cytoplasmic endonucleases and proteases that degrades nuclear 
materials and nuclear and cytoskeletal proteins, respectively, resulting in 
elimination of abnormal cells [33]. Evasion from apoptosis is a hallmark of 
cancer cells leading to an uncontrolled proliferation of damaged cells and 
contributing to cancer development that enhances resistance to 
conventional anti-cancer therapies, such as radiation and cytotoxic 
therapies. Most chemotherapeutic agents induce cancer cell death by the 
activation of the apoptotic pathway. However, most current 
chemotherapeutic drugs are associated with cytotoxic side-effects and the 
development of chemo-resistance [34, 35].  
1.5. Cell Cycle Control 
The cell cycle is series of integrated events controlled by a complex 
series of cellular and molecular signaling pathways by which a cell grows, 
replicates its DNA and divides. This process also includes mechanisms to 
ensure the fidelity of genetic material and corrects errors through 
checkpoints; if not, the cells commit suicide (apoptosis) [36, 37].  
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The cell cycle consists of four phases (G1, S, G2 and M). It 
governs the transition from quiescence (G0) to cell proliferation. As a cell 
approaches the end of the G1 phase, it is controlled at a checkpoint, 
called G1/S, where the cell determines whether or not to replicate its DNA. 
At this checkpoint the cell is checked for DNA damage to ensure that it 
has all the necessary cellular machinery to allow for successful cell 
division. As a result of this checkpoint, which involves the interaction of 
various proteins, a molecular switch is switched on or off. Cells with intact 
DNA continue to S phase while cells with damaged DNA are arrested and 
commit suicide through apoptosis, or programmed cell death. A second 
such checkpoint occurs at the G2 phase following the synthesis of DNA in 
S phase but before cell division in M phase [38, 39].  
In eukaryotes, regulation of the cell cycle is controlled, in part, by a 
family of protein kinase complexes, and each complex is composed 
minimally of a catalytic subunit, the Cyclin Dependent Kinases (CDKs), a 
specific enzyme family that uses signals to switch on cell cycle 
mechanisms. At least nine structurally related CDKs (CDK1- CDK9) have 
been identified. CDKs themselves are activated by forming complexes 
with an essential activating partner, cyclin, and another group of 
regulatory proteins that are only present for short periods in the cell cycle. 
These complexes are activated at specific intervals during the cell cycle 
by phosphorylation at specific sites on the CDK by CDK-activating kinase 
(CAK), but can also be induced and regulated by exogenous factors. 
During the progression of the cell cycle, the cyclin-CDK complexes are 
subject to inhibition through binding with a class of proteins known as 
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Cyclin Dependent Kinase Inhibitors (CDKIs), such as the CIP/KIP and 
INK4 families of proteins [37, 40-42].  
In mammalian cells CDKIs are grouped into two classes: (1) p21 
(Cip1/Waf1/Cap20/Sdi1/Pic1), p27 (Kip1), and p57 (Kip2) are related 
proteins with a preference for Cdk2-and Cdk4-cyclin complexes, (2) also 
p16lnk4a, p15lnk4b, p18lnk4c, and p191nk4d are closely related CDKIs 
specific for Cdk4- and Cdk6-cyclin complexes [43]. For instance, following 
stress signals or DNA damage, p21 and p27 bind to cyclin-CDK 
complexes to inhibit their catalytic activity, stop the cell from proceeding to 
the next phase of the cell cycle and induce cell-cycle arrest at different 
phases [44].  
A considerable number of cyclins have been identified (cyclin A–
cyclin T). The pattern of cyclin expression varies with a cell’s progression 
through the cell cycle, and this specific cyclin expression pattern defines 
the relative position of the cell within the cell cycle [45]. Cyclin D interacts 
with CDK2, -4, and -6 and drives cell progression through G1. The 
association of cyclin E with CDK2 is active at the G1/S transition and 
directs entry into S phase. S phase progression is directed by the cyclin 
A/CDK2 complex, and the complex of cyclin A with CDK1 is important in 
G2. CDK1/cyclin B is necessary for mitosis to occur [40, 46].  
When functioning properly, cell cycle regulatory proteins act as the 
body's own tumor suppressors by controlling cell growth and inducing the 
death of damaged cells [40]. However, any genetic mutations that cause 
the malfunction or absence of one or more of the regulatory proteins at 
cell cycle checkpoints can result in a molecular switch being turned 
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permanently on, permitting uncontrolled multiplication of the cell, leading 
to carcinogenesis, or tumor development [38].  
1.6. Cell Cycle Control and Cancer 
A dysregulation of the cell cycle is a hallmark of cancer in which, 
contrary to normal cells, tumor cells undergo unrestricted growth without 
stopping at predetermined points in the cell cycle. This is due to the 
inactivation of critical CDKIs, or to overexpression of cyclins. For instance, 
overexpression of cyclin D1 has been associated with the development 
and progression of breast cancer [37, 47]. Thus, abrogation of cell cycle 
checkpoints through targeting CDKs, CDKIs and/or cyclins would 
recapitulate cell cycle checkpoints that limit a tumor cell’s ability to cycle, 
and this may induce an apoptotic cascade leading to cell death [48]. 
Recent studies have suggested that cell cycle arrest in malignant cells is 
often associated with apoptotic cell death. In recent years, many studies 
have shown the involvement of cell cycle regulation-mediated apoptosis 
as a mechanism of cell growth inhibition [59-51] and such targeted 
therapy against cancer has become important as an ideal compound for 
the management of cancer. In clinical trials a series of targeted agents 
directly abrogate the cell cycle checkpoints at critical times and induce 
growth arrest to ultimately make the tumor cell susceptible to apoptosis 
[52, 53]. Examples of such agents include synthetic cell cycle inhibitors 
such as flavopiridol, olomoucine, roscovitine and puvalanol B which are 
considered to be a new generation of anticancer drugs [41, 54].  
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Interestingly, a number of natural compounds exerted their anti-
cancer activities through the induction of cell cycle arrest at different 
phases, which is considered as a promising chemopreventive and 
chemotherapeutic strategy, using more efficient and less toxic agents. 
Examples of some naturally occurring compounds that have induced cell 
cycle arrest, include capsaicin (chili peppers ), kaemopferol (broccoli and 
tea), apigenin (parsley and celery), tangeretin (citrus peels), catechins 
(tea), cyaniding (cherries and strawberries), 6-gingerol (ginger) and 
resveratrol (grapes and red wine) [55- 57].  
1.7. Cell Senescence  
Cell senescence is a stable cell cycle arrest that occurs in normal 
cells after a limited number of cell divisions. However, it is now broadly 
defined as a physiological program of terminal growth arrest [58]. It can be 
triggered by genetic manipulations or by different forms of stress such as 
treatment with chemotherapeutic drugs, radiation or differentiating agents 
[59]. Cells that undergo senescence do not proliferate even under mitogen 
stimulation, they remain viable and metabolically active but are 
permanently growth-arrested and produce secreted proteins such as ECM 
components that affect the growth of their neighboring cells (with both 
tumor-suppressing and tumor-promoting activities) as well as tissue 
organization. Even if not all of the tumor cells are rendered senescent as a 
result of an inducing agent (i.e. treatment), such cells may provide a 
reservoir of tumor-suppressing factors that will inhibit the growth of non-
senescent cells [60]. Growth arrest is achieved and maintained in either 
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the G1 or G2/M stage of the cell cycle, in part, by increased expression of 
specific cyclin-dependent kinase inhibitors (CDKIs), including p16Ink4a, 
p21Waf1 and p27Kip1 [61].  
Senescent cells develop distinct and recognizable flattened and 
enlarged cell morphology with a prominent nucleus and increased 
cytoplasmic granularity. Most notably, these cells can be visualized with a 
staining technique that is a widely accepted and used as a marker, 
senescence-associated β-galactosidase (SA-β-gal) activity, which is 
detectable by X-gal staining at pH 6.0, reflecting an increased lysosomal 
mass of senescent cells, and stains the perinuclear compartment blue 
[62].  
1.8. Senescence in Cancer Therapy 
Cancer therapy has traditionally been based on drug cytotoxicity 
that aims to complete the destruction of tumor cells to improve patient 
survival. This involves treatment with a high dose of toxic compounds or/ 
radiation. These approaches may produce complete cell death within a 
tumor, however, they have been found to cause severe side effects in 
patients and often develop drug resistance and relapse or progress to 
advanced primary and metastatic tumors [60]. An alternative strategy is 
the induction of senescence, which permanently stop the proliferative 
capacity of cells without inducing cancer cell death (cytostatic therapy). It 
is of clinical interest that cancerous cells can be induced to a senescent 
state in vitro and in vivo with specific conventional anticancer treatments. 
The induction of senescence in cancerous cells can sensitize cancerous 
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cells more to chemotherapy or radiation but by using lower doses. A 
senescence-induced response to chemotherapy has seen found to be 
induced by a wide variety of anticancer agents under conditions of 
minimal cytotoxicity. Recently, clinical studies utilizing cytostatic 
treatments have shown promising preliminary results where therapy 
induced senescence has been identified in tumors after radiation or 
chemotherapy [63-65]. Although senescence occurs only in a subset of 
treated cells, suggesting that these treatments may be as effective as 
cytotoxic therapies in inducing permanent growth inhibitory response in 
both early and late stage cancers, limiting tumor progression and 
providing equivalent or prolonged survival with reduced toxicity related 
side effects. Moreover, evidence suggests that therapy inducing 
senescence may function as a back-up response to therapy in cancer 
cells in which apoptotic pathways are disabled [66]. Therefore, activating 
senescence in tumor cells is another attractive approach to cancer 
treatment.  
Senescence is not the only anti-proliferative response that 
determines treatment responses in the absence of apoptosis. Another 
principal mechanism for anticancer agents is mitotic catastrophe; cell 
death resulting from abnormal mitosis; which usually ends in the formation 
of large cells with multiple micronuclei and uncondensed chromatin [67]. 
Etoposide-induced mitotic catastrophe in HeLa cells was greatly increased 
when apoptosis was inhibited by BCL-2 [68]. Also, both mitotic 
catastrophe and senescence were shown to be induced in irradiated 
tumor cells when apoptotic responses were suppressed [69].  
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1.9. Natural Sources As Potential Anti-Cancer Agents 
Among the potential alternatives for treating cancer are anti-cancer 
agents from natural sources such as plants and dietary phytochemicals, 
marine organisms and microorganisms. Throughout history, nature has 
been an attractive and rich source of new therapeutic compounds that 
have found many applications in cancer therapy, as a tremendous 
chemical diversity can be found in millions of species of plants, animals, 
marine organisms and microorganisms [70]. Over 70% of all anti-cancer 
compounds are either natural products, or natural product-derived 
substances or their derivatives (chemically-altered products) that were 
developed on the basis of knowledge gained from small molecules or 
macromolecules that exist in nature [71]. Chemoprevention and 
chemotherapy by naturally occurring agents is now considered to be more 
effective, and they do not have large side-effect consequences compared 
to synthetic drugs. It is an inexpensive, readily applicable, acceptable and 
accessible approach to cancer prevention and treatment [72].  
Recent studies have shown that compounds isolated from natural 
sources have cytotoxic effects on several types of cancer cells, like 
breast, colon, melanoma, uterine, lung and leukemia cells. Moreover, 
studies suggest that the consumption of food rich in fruit, vegetables and 
spices results in a lower incidence of cancers (stomach, oesophagus, 
lung, oral cavity and pharynx, endometrium, pancreas and colon) [56, 70, 
71].    
Between 2001 and 2005, four new drugs derived from natural 
products were approved as anti-cancer agents. The approved anti-cancer 
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agents doxorubicin, estradiol in 2002, cholorophyll and l-aspartic acid in 
2004 and taxol nanoparticles in 2005 [73]. The marine alkaloid 
trabectedin, epothilone derivative ixabepilone and temsirolimus are three 
new drugs introduced in 2007 that originated from microbial sources for 
the treatment of cancer [74].  
1.9.1. Phytochemicals: Dietary Source of Anti-Cancer Agents  
 
Phytochemicals are natural plant-derived compounds that have 
been shown to influence human health in many ways. Plants have been a 
rich source of highly effective phytochemicals which offer great potential in 
the fight against cancer. More than 1,000 different phytochemicals have 
already been prove to possess interesting chemo-preventing activities. 
Phytochemical are becoming more attractive for cancer prevention and 
treatment because they were proven to be very effective, and do not have 
serious side-effects compared to synthetic drugs and most importantly, 
they can act on specific and/or multiple molecular and cellular targets. 
Recently, these natural compounds have become of increasing interest 
thanks to their health promoting properties, especially with regard to 
breast cancer treatment and prevention [71, 75]. 
Identification and development of new chemotherapeutic agents 
from plants have been recognized in cancer therapy, and have become 
major areas for experimental cancer research. Various phytochemicals 
present in the diet were found to (i) kill breast cancer cells in vitro and (ii) 
prevent and/or suppress breast cancer progression in various preclinical 
animal models [76]. Phytochemicals have been shown to target breast 
cancer development and progression through inhibiting cellular 
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proliferation, suppressing inflammatory processes, arresting cell cycles, 
inducing apoptosis, modulating gene expression such as upregulation of 
cytoprotective genes that encode for carcinogen detoxifying enzymes and 
antioxidant enzymes and/or upregulation of tumor suppressing genes that 
encode for tumor suppressor proteins that play an important roles in 
cellular signaling pathways, and inhibiting angiogenesis and invasion 
potential of many metastatic cancer cell line [77].  
Thus, cell signaling cascades and their interacting factors have 
become important targets of chemoprevention and chemotherapy in which 
phytochemicals and plant based agents seem to be effective. The 
mechanistic insight into chemoprevention further includes induction of cell 
cycle arrest and apoptosis, or inhibition of signal transduction pathways, 
mainly the mitogen-activated protein kinases (MAPK), protein kinases C 
(PKC), phosphoinositide 3-kinase (PI3K), glycogen synthase kinase 
(GSK) which lead to abnormal cyclooxygenase-2 (COX-2), activator 
protein-1 (AP-1), NF-κB and c-Myc expression. The effectiveness of 
chemopreventive agents reflects their ability to counteract certain 
upstream signals that lead to genotoxic damage, redox imbalances and 
other forms of cellular stress [77]. 
Bioactive natural compounds and the modulated molecular targets 
identified through extensive research can be the basis for how these anti-
cancer agents can potentially be used for the prevention and treatment of 
cancer. However, a lack of success with targeted monotherapy, resulting 
from evading mechanisms, has forced researchers to employ either 
combination therapy or agents that interfere with multiple cell-signaling 
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pathways. Numerous anti-cancer agents and phytochemicals identified 
from plants can interfere with cell-signaling pathways. Examples of 
anticancer drugs derived from plants and currently in clinical use include 
the vinca alkaloids (vinblastine and vincristine) isolated from Catharanthus 
roseus. The Vinca alkaloid was responsible for an increase in the cure 
rates of some forms of leukemia [78]. Vincristine was shown to inhibit 
microtubule assembly, inducing tubulin self-association into coiled spiral 
aggregates [78]. Etoposide is an epipodophyllotoxin, derived from the 
mandrake plant Podophyllum peltatum and the wild chervil Podophyllum 
emodi [79] and displayed significant promise against small-cell lung 
carcinomas [80]. Etoposide is a topoisomerase II inhibitor, stabilizing 
enzyme–DNA cleavable complexes leading to DNA breaks [81]. The 
taxanes paclitaxel and docetaxel show antitumor activity against breast, 
ovarian and other types of tumor in clinical trials. Paclitaxel stabilizes 
microtubules leading to mitotic arrest [82]. In addition, the camptothecin 
derivatives irinotecan and topotecan, have shown significant antitumor 
activity against colorectal and ovarian cancer, respectively [83, 84]. These 
later compounds were initially obtained from the bark and wood of 
Nyssacea Camptotheca accuminata and act by inhibiting topoisomerase 
[85]. The taxanes and the camptothecins are approved for human use in 
various countries.   
Synthetic flavone, a cyclin-dependent kinase inhibitor, derived from 
rohitukine, is a plant alkaloid isolated from the leaves and stems of 
Dysoxylum binectariferum [86, 87].  Flavopiridol represents the first cyclin-
dependent kinase inhibitor to enter clinical trials [88]. Its mechanism 
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involves interfering with the phosphorylation of cyclin-dependent kinases 
and arresting cell-cycle progression at the growth phases G1 or G2 [89, 
90]. 
Homoharringtonine, another alkaloid isolated from the 
Cephalotaxus harringtonia tree, is efficient against various forms leukemia 
[91, 92].  Its mechanism involves the inhibition of protein synthesis and 
blocking cell-cycle progression [93]. DNA topoisomerase I inhibitor β-
lapachone, originally obtained from the Lapacho tree, induces cell-cycle 
delay at the G1 or S phase before inducing either apoptotic or necrotic cell 
death in a variety of human carcinoma cells, including ovaries, colon, 
lungs, prostate and breast [94]. Moreover, there are many plants which 
are known to suppress cancers that need further studies to validate their 
potential anticancer activities. Examples include Salvia officinalis, Viscum 
album, Broussonetia papyrifera, Euphorbia heterophylla, and Viscum 
calcaratum. About 117 plants were reviewed in ref. [70] for their anti-
cancer activity. 
1.9.1.1. Origanum majorana 
Origanum majorana belongs to the family Lamiaceae. It is 
commonly known as marjoram. It is a perennial herb and widespread 
worldwide. A large number of known species of the genus Origanum are 
utilized worldwide as spices and flavoring agents and have a long history 
of both culinary and medicinal use. O. majorana is used as a home 
remedy for chest infections, coughs, sore throats, rheumatic pains, 
nervous disorders, stomach disorders, cardiovascular disease and skin 
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care [95, 96]. Many such traditional uses of the marjoram species were 
confirmed in several studies utilizing both in vitro and in vivo approaches. 
Several reports indicate that O. majorana is very rich in phenolic 
compounds. The high phenolic content in Origanum has a capacity to 
scavenge free radicals to be associated with strong antioxidant activity 
[97]. O. majorana contains phenolic terpenoids (thymol and carvacrol), 
flavonoids (diosmetin, luteolin, and apigenin), tannins, hydroquinone, 
phenolic glycosides (arbutin, methyl arbutin, vitexin, orientin, and 
thymonin) and triterpenoids (ursolic acid and oleanolic acid) [98]. 
O. majorana has been reported to exhibit significant anti-microbial 
activity [99]. Several studies have also demonstrated that ethanolic, 
aqueous extracts and the essential oil of O. majorana could protect 
against liver and kidney damage and genotoxicity induced by lead acetate 
[100-102]. O. majorana has also been found to inhibit platelet adhesion 
aggregation and secretion [103]. Furthermore, this plant exerts a low 
cytotoxicity on several hepatoma cell lines [104]. It has been shown by Al 
Harbi that an extract of O. majorana reduced the side effects induced by 
cyclophosphamide, an established anticancer drug, without altering its 
cytotoxicity [96]. 
In the present study, we investigated the effect of Origanum 
majorana ethanolic extract (OME) on breast cancer cells. We examined 
the effects of OME on cell viability, cell cycle, apoptosis and tumor 
invasion and metastasis in the highly proliferative and invasive Estrogen 
Receptor (ER)-negative mutant p53 breast cancer cell line MDA-MB-231.  
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1.9.2. Microorganisms as Source of Anti-Cancer Agents  
Many anti-cancer agents have been discovered by screening 
natural products from a wide range of microorganisms. Toxins that 
originally evolved to kill competing microorganisms can have a variety of 
physiological effects in animals. In many cases, the targets of these 
compounds are components of signal transduction cascades that are 
conserved in many species, and that have been considered novel targets 
for anticancer drug discovery [105].   
Anti-tumor antibiotics are among the most important cancer 
chemotherapeutic agents, and include members of the anthracycline, 
bleomycin (isolated from Streptomyces verticillus and used in treatment of 
germ-cell, cervix and head and neck cancers), actinomycin (isolated from 
Streptomyces spp. and used to treat sarcoma and germ-cell tumors) 
[106]. Clinically useful agents from these above families are the 
daunomycin (isolated from Streptomyces coeruleorubidus and used to 
treat leukemia) and related agents like doxorubicin, idarubicin, and 
epirubicin (isolated from Streptomyces Pneuceticus and used in 
lymphoma, sarcomas, breast, ovary, lung cancers).  
Rapamycin and its analogs are products of Streptomyces 
hygroscopicus that have potent immunosuppressive activity. They inhibit 
the signaling pathways required for T-cell activation and proliferation. 
Rapamycin blocks progression of the cell cycle at the middle-to-late G1 
phase in T cells and B cells, and osteosarcoma and rhabdomyosarcoma 
cell lines, among others [107]. Geldanamycin is a benzoquinone 
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ansamycin natural fermentation product and inhibits the heat-shock 
protein HSP 90 [108].  
Wortmannin is a product of the fungus Talaromyces wortmanni and 
inhibits signal transduction pathways by forming a covalent complex with 
an active-site residue of phosphoinositide 3 kinase (PI3K), inhibiting PI3K 
activity [109]. Others include also the peptolides (i.e. dactinomycin), the 
mitosanes (such as mitomycin C) and the glycosylated anthracenone 
mithramycin. The anthracyclines are among the most used anti-tumor 
antibiotics in the clinic and exert anti-tumor activity mainly by inhibiting 
topoisomerase II [110]. 
Anti-cancer agents from natural sources exert their toxicity through 
modulation of several pathways and induction of different mechanisms of 
cell death and growth inhibition. Such anti-cancer agents from natural 
sources induce apoptosis, necrosis, growth arrest, senescence, and 
autophagocytosis in several types of cancer. Growth inhibition and 
induction of cell death are among the major objectives of anti-cancer 
therapies.  
1.9.2.1. Salinomycin 
Salinomycin is a monocarboxylic polyether antibiotic, isolated from 
Streptomyces albus, widely used as an antibiotic to prevent 
anticoccidiosis in poultry and as growth promoter for ruminants and swine.   
Screening for compounds that specifically target cancer stem cells has led 
to the identification of Salinomycin as potential anticancer agent. 
Salinomycin was shown to (i) selectively induce cell death in breast 
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cancer stem cells in cell culture assay and (ii) inhibit breast tumor growth 
in mice [111]. More recent investigations have reported that Salinomycin 
possesses a potent anticancer activity against other cancer stem cells 
such as the ALDH positive A549 lung cancer cells [112], ALDH gastric 
cancer cells [113], and CD133+ subpopulations in human CRC HT29 and 
SW480 colorectal cancer cells [114]. However, the mechanism of 
Salinomycin's activity on cancer stem cells is yet to be elucidated.   
More recent studies reported that Salinomycin shows efficacy 
against other human cancer cells including those displaying drug 
resistance [115]. Salinomycin was shown to act as a p-glycoprotein 
inhibitor to overcome apoptosis resistance in cancer cells [116]. Lu, et al., 
2010, have shown that Salinomycin inhibits Wnt signaling and selectively 
induces apoptosis in chronic lymphocytic leukemia cells [117]. 
Salinomycin was also shown to induce apoptosis in human prostate 
cancer cells by inducing an elevation in the intracellular reactive oxygen 
species (ROS) levels and mitochondrial membrane depolarization [118]. 
Very recent studies have also shown that Salinomycin inhibits prostate 
cancer growth and migration through the induction of oxidative stress 
[119].  
A combination treatment using Salinomycin with gemcitabine has 
proven to be more effective than individual drugs against pancreatic 
cancer cells [120]. It appears that Salinomycin sensitizes cancer cells to 
the effects of etoposide and doxorubicin treatments by enhancing 
apoptosis, increasing DNA damage and reducing the level of p21 protein 
[121]. Indeed, Salinomycin sensitizes radiation-treated cells by inducing 
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G2 arrest and causing DNA damage [122]. More recently, Salinomycin 
was reported to sensitize cancer cells to antimitotic drugs (paclitaxel, 
docetaxel, vinblastin and colchicine) by enhancing apoptosis as well as 
preventing G2 arrest [123].  
Despite the recent findings, the mechanisms underlying the 
anticancer activity of Salinomycin are still poorly understood. In the 
present study, we have investigated the effect of Salinomycin on MCF-7, 
T47D and the triple negative MDA-MB-231 human breast cancer cell 
lines.  
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SPECEIFIC AIMS OF THE STUDY (OBJECTIVES) 
1. Testing the efficacy of Origanum majorana plant extract and 
Salinomycin against different types of human breast cancer in vitro 
(cancer cell lines) and in vivo (chick embryo tumor growth and 
metastasis assay).  
In this study, the effects of this plant extract and this compounds on cell 
viability, apoptosis, migration and invasion in vitro and the progression 
and metastasis of human solid breast tumors in vivo were evaluated.  
2. Identification of downstream biomarkers associated with response 
to the treatment with selected active plant extracts. 
Because most anticancer drugs are known to alter gene expression, we 
examined the effects of the O. majorana extract and Salinomycin on the 
expression of pathways (apoptosis, cell cycle…)- specific genes in several 
breast cancer cell lines using western blot, immunofluorescence and RT-
PCR analysis.  
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CHPATER 2: MATERIALS AND METHODS 
2.1. Preparation of the Origanum majorana Ethanolic Extract 
Origanum majorana commonly known as “marjoram” and used as a 
culinary herb was obtained from a private commercial farm located in the 
Tyre region of Lebanon. All necessary permits were obtained for the 
harvesting of the leaves. 5.0 g of the dried leaves were ground to a fine 
powder using a porcelain mortar and pestle. The powder was suspended 
in 100 mL of 70% absolute ethanol and the mixture was kept in the dark 
for 72 hours at 4°C in a refrigerator without stirring. The mixture was then 
filtered through a glass sintered funnel and the filtrate was evaporated 
using a rota-vapor at room temperature. The green residue was kept 
under vacuum conditions for 2–3 hours and its mass was recorded. 
2.2. Cell Culture and Reagents 
Human breast cancer cells MDA-MB-231 and MCF-7 were 
maintained in DMEM (Hyclone, Cramlington, UK) and the MDA-MB-23-
GFP used in this study was maintained as previously described [124]. The 
T47-D breast cancer cells were maintained in RPMI 1640 (Hyclone). All 
media were supplemented with 10% fetal bovine serum and 100U/ml 
penicillin/streptomycin (invitrogen). HUVECs (Invitrogen, Carlsbad, CA, 
USA) were maintained in MEM 199 supplemented with 20% FBS, 
penicillin/streptomycin, 2 mM L-glutamine, 5U/ml heparin and 50 μg/ml 
endothelial cell growth supplements (BD Biosciences, Bedfrord, MA, 
USA). Salinomycin and 4-Hydroxy-Tamoxifen were purchased from 
Sigma-Aldrich (Saint-Quentin Fallavier; France).  Antibodies for p21 
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(556431), PARP (556494) were obtained from BD Pharmingen. 
Antibodies for phosphor-H2A.X (ser139) (07-164), acetyl-Histone H3 (06-
599), acetyl-Histone H4 (06-866), phosphor-Histone H3 (ser10) (05-1336), 
P53 (E26, 04-241), Cyclin B1 (05-373) and cyclin D1 (04-1151) were 
obtained from Millipore. Antibodies for survivn (sc-1779), ICAM-1 (sc-107), 
β-actin (C4, sc-47778), goat anti-mouse IgG-HRP (sc-2005) and goat anti-
rabbit IgG-HRP (sc-2004) were obtained from Santa Cruz Biotechnology, 
Inc. Antibodies to E-cadherin (ab15148), TNF- (ab9739) and uPAR (ab 
103791) from Abcam. Antibodies to p27 (3686), NF-kB p65 (3034), pIB-α 
(ser32) (2859) from Cell Signaling (Cell Signaling Technology, Inc., 
Danvers, MA, USA). AlexaFluor 488 goat anti-rabbit IgG (H+L) (A11008) 
and AlexaFluor 594 goat anti-mouse IgG (H+L) (A11005) were obtained 
from Invitrogen.  
2.3. Cellular Viability 
Cells were seeded in triplicate in 96-well plates at a density of 
5,000 cells/well. After 24 hours of culture, cells were treated with 
increasing concentrations of Salinomycin or OME and incubated for the 
indicated time periods. Control cells were exposed to DMSO cells (in case 
of Salinomycin) at a concentration equivalent to that of the Salinomycin-
treated or equal volume of 70% ethanol (in case of OME).  In combination 
experiments, MCF-7 and MDA-MB-231 cells were subjected to 
simultaneous treatment with 20 µM 4-hydroxy-tamoxifen A and 1µM 
frondoside A, respectively, plus DMSO or increasing concentrations of 
Salinomycin for 48 hours. The effects of Salinomycin, alone or in 
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combination, on cell viability was determined using a CellTiter-Glo 
Luminescent Cell Viability Assay (Promega Corporation, Madison, USA), 
based on quantification of ATP, which signals the presence of 
metabolically active cells. Luminescent signals were measured using a 
Berthold FB12 Luminometer. The Data were presented as proportional 
viability (%) by comparing the treatment group with the untreated cells, the 
viability of which is assumed to be 100%.  
Cell viability was also assessed using Trypan Blue Exclusion 
Assay. Cells were plated onto 24-well plates (20 x 104 cells/well). The day 
of the treatment the cells were counted to estimate the approximate 
number of cells per well. Following Salinomycin treatment at indicated 
times, cells were trypsinized, pelleted by centrifugation and resuspended 
in serum free DMEM and stained with trypan blue. Dead (stained blue) 
and live (unstained) cells were counted on a Neubauer Hemacytometer. 
Three independent assays were performed in triplicate, and results were 
reported as the means ± SEM. 
2.4. Caspase 3/7, 8 and 9 activities 
MDA-MB-231, MCF-7 cells were seeded at a density of 5,000 cells 
/ well into a 96-well plate in triplicate and treated with the drugs for 24 
hours and 48 hours. Caspase-3/7, 8 and 9 activities were measured using 
a luminescent Caspase-Glo 3/7, Caspase8 and Caspase 9 assay kits 
(Promega Corporation, Madison, USA) following the manufacturer’s 
instructions. Caspase reagents were added to triplicate in the 96 wells. 
The plate was mixed on an orbital shaker and incubated for 2.5 hours at 
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room temperature in the dark. A luminescent signal was measured as 
described above.  
2.5. Senescence Associated-β-Galactosidase (SA-β-gal) Staining 
2.5 x105 MDA-MB-231 cells were cultured in 60mm culture dishes 
for 24 hours and then exposed to Salinomycin 10µM or DMSO for 96 
hours. Treatment and control cells were then washed in PBS, and fixed 
with 2% formaldehyde/ 0.2% glutaraldehyde for 5 minutes at room 
temperature. The SA-β-gal staining was conducted as previously 
described [125]  
2.6. Flow Cytometric Analysis of Cell Cycle 
MDA-MB-231 cells (1.8 x106) were seeded in 100mm culture 
dishes and cultured for 24 hours before the addition of either OME extract 
or Salinomycin at the concentrations indicated in the results part. After 
incubation, cells were harvested, washed twice with ice-cold PBS, 
resuspended in 500µl PBS, fixed with an equal volume of 100% ethanol 
and incubated for at least 12 hours at -20ºC.  Cells were then pelleted, 
washed twice with PBS, permeabilized in 0.1% Triton X-100/PBS for 15 
minutes on ice, pelleted and then resuspended in PBS containing 40µg/ml 
propidium iodide and 25µg/ml RNase A, at 37ºC for 30 minutes. Cells 
were analyzed using BD FACSCanto II (Becton Dickinson). Data 
acquisition was conducted using FACSDiva 6.1 software. The percentage 
of cells in the G1, S and G2/M phases were determined using the FlowJo 
software. 
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2.7. Quantification of Apoptosis by Annexin V /Propidium iodide (PI) 
Staining 
DMSO and Salinomycin-treated MDA-MB231 (1.8 x 106) cells 
grown in 100mm culture dishes were harvested by trypsin release and 
washed twice with ice-cold PBS. Apoptotic cell death was determined 
using the BD FITC Annexin V Apoptosis Detection Kit II (BD Biosciences) 
according to the manufacturer’s instructions. Cell samples were analyzed 
using the BD FACSCanto II (Becton Dickinson). 
2.8. Immunofluorescence Staining 
 MDA-MB 231 cells (4 x104) were grown on 4 well labtek chamber 
slide (Becton Dickinson) for 24 hours, and then treated with vehicle as 
control or either OME extract or Salinomycin for 24 hours at the 
concentrations indicated in the results come later. Cells were then fixed in 
10% formalin solution (4% paraformaldehyde) (Sigma-Aldrich; Saint-
Quentin Fallavier, France) for 5 minutes at room temperature followed by 
permeabilization in PBS containing 0.1% Triton X-100 for 5 minutes at 
room temperature. Cells were then washed three times with PBS, blocked 
with 5% non-fat dry milk in PBS for 30 minutes at room temperature and 
then incubated with the primary antibody diluted in 1% non-fat dry 
milk/PBS overnight at 4ºC. Following incubation, cells were washed three 
times with PBS and incubated for 1 hour at room temperature in the 
presence of rhodamine-conjugated or fluorescein-conjugated secondary 
antibody diluted at 1:200 in 1% non-fat dry milk/PBS. After washing with 
PBS, cells were mounted in Fluoroschield with DAPI (Sigma-Aldrich) and 
examined under Nikon Ti U fluorescence microscope. 
 31 
 
2.9. Colony Formation Assay in Soft Agar 
Assays were performed in six-well plates. The lower (base) layer 
consisted of 1 ml 2.4% Noble Agar. The base layer was overlaid with a 
second layer consisting of 2.9 ml growth medium, 0.3% Noble Agar, and 3 
× 104  MDA-MB-231 cells. Agar at 50°C was mixed with the medium at 
37°C, plated, and left to set for 10 minutes. Growth medium was then 
added and plates incubated at 37oC. Cells were allowed to grow to form 
colonies for 14 days before treatment with either Salinomycin or OME 
extract. Colonies were allowed to grow for one more week. Following 
treatment, plates were washed twice with PBS and then colonies were 
fixed with 10% ice-cold methanol for 10 min and washed once with PBS. 
Colonies were allowed to stain for 1 hour in a solution containing 2% 
Giemsa. The size of the colonies was measured, using a microscope 
(10X) and the colony size was categorized as Large (>400 µm), medium 
(200-400 µm), or small (50-200 µm). Colony sizes were expressed as a 
percentage of total counted colonies and then compared to the vehicle 
treated controls (DMSO). The experiment was repeated three times. 
2.10. Nuclear and whole Cell Extract and Western Blot Analysis 
Cells (1.8 x 106) were seeded in 100mm culture dishes and 
cultured for 24 hours before the addition of various concentrations of 
either Salinomycin or OME extract. For whole cell lysates, following 
incubation, cells were washed twice with ice-cold PBS, scraped, pelleted 
and lysed in RIPA buffer (89900, Pierce) supplemented with a 
protease/phosphatase inhibitor cocktail (1861281, Pierce). After 
incubation for 30 minutes on ice, cell lysates were centrifuged at 14,000 
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rpm for 20 minutes at 4ºC. Nuclear extract were prepared from vehicle-or 
OME-treated MDA-MB-231 cells using the NE-PER extraction reagents 
(Thermo Scientific, Rockford, IL, USA). The protein concentration of the 
lysates was determined using BCA Protein Assay Kit (23225, Thermo 
Scientific) and the lysates were adjusted with lysis buffer. Aliquots of 25 
µg of total cell lysate were resolved onto 10-12% SDS-PAGE. Proteins 
were transferred to nitrocellulose membranes (88018, Thermo Scientific) 
and blocked for 1 hour at room temperature with 5% non-fat dry milk in 
TBST (TBS and 0.05% Tween 20). Incubation with specific primary 
antibodies was conducted in a blocking buffer overnight at 4ºC. 
Horseradish peroxidase-conjugated anti-IgG was used as secondary 
antibody. Immunoreactive bands were detected by ECL chemiluminescent 
substrate (32209, Thermo Scientific). Also when needed, membranes 
were stripped in a Restore Western Blot Stripping Buffer (21059, Thermo 
Scientific) according to the manufacturer’s instructions.  
2.11. Wound Healing Migration Assay 
MDA-MB-231 cells were grown in six-well tissue culture dishes until 
confluence. A scrape was made through the confluent monolayer with a 
sterile plastic pipette tip of 1mm diameter. Afterwards, the dishes were 
washed twice with PBS and incubated at 37°C in fresh DMEM 
complemented with 10% fetal bovine serum in the presence or absence of 
the indicated concentrations of OME. At the bottom side of each dish, 
three arbitrary places were marked where the width of the wound was 
measured with an inverted microscope (objective x 10). Wound closure 
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was expressed as the average ± SEM of the difference between the 
measurements at time zero and a 10 hours' time period. 
2.12. Migration Chamber Assay 
5 x 104 cells were seeded in the upper chamber, HTS Multiwell 
Insert System (BD Biosciences, Franklin Lakes, NJ, USA), in serum-free 
medium, with or without OME and migration assay, A serum-containing 
medium was added to the lower chamber to act as a chemotactic 
attractant. After 6 hours of incubation, cells were washed with PBS, and 
fixed with formaldehyde. Cells were then stained with 1% crystal violet for 
10 minutes. After washing with PBS, cells from at least 5 different random 
fields were counted under a microscope. 
2.13. Aggregation Assay 
Growing cells were detached using a 2mM EDTA in calcium 
magnesium-free PBS (CMF-PBS). A cell suspension of 1 x 106 cells/ml 
was aliquoted into microcentrifuge tubes, washed with PBS, resuspended 
in a 1ml culture media and incubated with or without OME on a rocker for 
1 hour at 37°C. Cells were then fixed with 1% formaldehyde and pictures 
taken under an inverted microscope (Olympus IX71). Aggregation was 
calculated as previously reported [126] using the following equation: % 
aggregation= (1-Nt/Nc) x 100, where Nt and Nc represent the number of 
single cells in treatment and untreated groups, respectively. 
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2.14. Adhesion Assay 
Adhesion of MDA-MB-231 to HUVECs was performed as 
previously described [127] with minor modifications. Cell culture plates 
were coated with collagen and HUVECs grown to confluent monolayers. 
TNF-α (25ng/ml) was added for 6 hours to stimulate HUVECs prior to the 
addition of MDA-MB-231 cells. MDA-MB-231 transfected with Renilla 
Luciferase were resuspended in HBSS containing a 1% BSA at a 
concentration of 2x105 cells/ml. 150 µl of this cell suspension was added 
to the upper chamber containing confluent HUVECs in the absence or 
presence of OME. After 1 hour, unattached cells were removed by gently 
washing the plates three times with PBS. Adherent cells were lysed using 
a luciferase lysis buffer (Promega, Madison, WI, USA) and light units were 
measured.  
2.15. Matrigel Invasion Assays 
The invasiveness of the MDA-MB-231 cell was treated with the 
indicated concentrations of OME and tested using a BD Matrigel Invasion 
Chamber (8-µm pore size: BD Biosciences, Bedfrord, MA, USA). MDA-
MB-231 (1 x 105) cells were placed in 0.5 mL of media containing vehicle 
or the indicated concentrations of OME were seeded into the upper 
chambers of the system. The bottom wells in the system were filled with 
DMEM complemented with 10% fetal bovine serum as a chemo-attractant 
and then incubated at 37°C for 24 hours. Non-penetrating cells were 
removed from the upper surface of the filter with a cotton swab. Cells that 
have migrated through the matrigel were fixed with 4% formaldehyde, 
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stained with DAPI and counted in 6 random fields under a microscope. 
For quantification, the assay was done in duplicate then and repeated 
three times. 
2.16. Measurement of Matrix Metalloproteinases by ELISA 
Cells were seeded in 6-well plates in the absence of vehicle or 
OME for 24 hours. The conditioned medium was collected and the levels 
of MMP-2 and MMP-9 secreted were determined using immunoassay kits 
(Invitrogen, Camarillo, CA, USA). The experiments were repeated three 
times and the average of the three means was represented as ± SEM.  
2.17. Gelatin Zymography 
Gelatin zymography was conducted as previously described [128]. 
MDA-MB-231 (2.5 x 106) cells were incubated in serum-free DMEM for 24 
hours in the presence of vehicle or OME (150 and 300 µg/mL). The 
conditioned medium was collected, concentrated and 30 μg of total 
protein was resolved in 10% polyacrylamide gel containing 0.1% gelatin. 
After electrophoresis, the gel was washed for 1 hour in 2.5% (v/v) Triton 
X-100 to remove SDS and then incubated overnight at 37°C in 50 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 mM ZnCl2 and 10 mM CaCl2 to allow 
proteolysis of the gelatin substrate. Bands corresponding to activity were 
visualized by negative staining using 0.5% Coomassie brilliant blue R-250 
(Bio-Rad, Hercules, CA, USA). Representative results from two 
independent experiments are shown. Densitometry was conducted using 
ImageJ software and the band density was normalized to the non-specific 
band staining on the gel. 
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2.18. Quantitative Immunoassay for Human Vascular Endothelial 
Growth Factor (VEGF) 
MDA-MB-231 cells (1.5 x 105) were seeded in 24-well plates. The 
conditioned medium was collected and the level of VEGF measured using 
a VEGF Enzyme-Linked Immunosorbent Assay Kit (R&D Systems, 
Minneapolis, MN, USA. Assays were performed in triplicate and three 
independent experiments were conducted. The data is presented as mean 
values ± SEM. 
2.19. Quantification of Nitrate/Nitrite Production 
The amount of nitrate/nitrite production was determined with a 
colorimetric ELISA Kit (Cayman Chemical, Ann Arbor, Michigan, USA), 
which is based on the Griess reaction. The value of nitrate/nitrite 
presented is the total value measured in the presence of cells minus the 
value determined from the media alone in the absence of any growing 
cells. 
2.20. Luciferase Activity 
MDA-MB-231 cells were seeded in 12-well plates the day before 
transfection. Cells were then transfected with the E-cadherin Luciferase 
Reporter Expression Plasmid [129] using Lipofectamine 2000 (Life 
Technologies, Inc. Grand Island, NY, USA). Cells were allowed to recover 
for 4 hours after transfection in OPTI-MEM (Life Technologies, Inc., Grand 
Island, NY, USA) which was then replaced with a complete medium. 
Luciferase activity was measured using Dual Luciferase Reporter Assay 
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System (Promega, Madison, WI, USA). Renilla Luciferase reporter was 
used as an internal control, to which firefly luciferase values were 
normalized. Experiments were repeated three times and the average of 
the three means was represented ± SEM.  
2.21. Transendothelial Migration Assay 
Transendothelial migration of MDA-MB-231 through HUVEC was 
conducted as previously described [130]. Transwell filters were coated 
with collagen and allowed to dry overnight. HUVECs (2 X 105/well) were 
then seeded onto the rehydrated membrane and allowed to grow until a 
confluent monolayer was formed. TNF-α (25ng/ml) was added for 6 hours 
to stimulate HUVECs. Then, MDA-MB -231 cells (1 x 106) were loaded on 
top and incubated overnight in the absence, or presence, of OME. Cells 
on the upper chamber were removed with a cotton swab, whereas MDA-
MB-231 on the bottom were stained and quantified as previously reported 
[130].  
2.22. RNA Extraction and RT-PCR 
Total RNA from vehicle- or OME-treated MDA-MB-231 cells were 
prepared using Trizol reagent (Life Technologies, Inc. Grand Island, NY, 
USA). The RNA expression of MMP-2 and MMP-9 was determined by RT-
PCR. RT-PCR was performed using the Qiagen OneStep RT-PCR Kit 
(Qiagen, Hilden, Germany). Equal amounts of RNA (500 ng) were used as 
templates in each reaction. The sequences of specific primers were as 
follows: MMP-2 sense, 5′-TCTCCTGACATTGACCTTGGC-3′, and 
antisense: 5′-CAAGGTGCTGGCTGAGTAGATC-3′; MMP9 sense, 5′- 
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TTGACAGCGACAAGAAGTGG-3′, and antisense, 5′- 
CCCTCAGTGAAGCGGTACAT-3′; GAPDH sense, 5′-
GGCCTCCAAGGAGTAAGACC-3′, and antisense: 5′- 
AGGGGTCTACATGGCAACTG-3′. The PCR products were separated by 
1.5% agarose gel and visualized by ethidium bromide staining. 
Representative results from two independent experiments are shown. 
2.23. Chick Embryo Tumor Growth and Metastasis Assay 
The chick embryo tumor growth assay was performed as previously 
described [131] with slight modifications.  According to French legislation, 
no ethical approval is needed for scientific experimentation using 
oviparous embryos (decree n°2013-118, February 1, 2013; art. R-214-88). 
This work was done under animal experimentation permit N°381029 
issued to Jean Viallet and animal experimentation permit N° 
B3851610001 issued to Institute Albert Bonniot. Fertilized White Leghorn 
eggs (Société Française de Production Agricole, St. Brieuc, France), were 
incubated at 38°C with 60% relative humidity for 10 days. At stage E10, 
the chorioallantoic membrane (CAM) was dropped by drilling a small hole 
through the eggshell into the air sac and a 1 cm2 window was cut in the 
eggshell above the CAM. Cultured MDA-MB-231-GFP were detached by 
trypsinization, washed with complete medium and suspended in serum 
free DMEM. A 50 µl inoculum of 1 X 106 MDA-MB-231-GFP cells was 
added onto the CAM of each egg (eggs were randomized in 4 groups of 
15). One day later, tumors that began to be detectable  were treated every 
second day at E11, E13, E15 and E17 by dropping 100 µl of either OME 
(300 µg/mL or 450 µg/mL), colchicine (2µM) or 0.02 % ethanol (vehicle) in 
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PBS onto the tumor. At E19 the upper portion of the CAM was removed, 
transferred in PBS and the tumors were then carefully cut away from 
normal CAM tissue and weighted. In parallel, a 1 cm2 portion of the lower 
CAM was collected to evaluate the number of nodules, containing GFP-
expressing cells. The fluorescent nodule were visualized in situ using 
whole mounts of tissue fixed in 4% formaldehyde in PBS and flattened 
between a hollow glass slide and a thick coverslip. In order to number the 
nodules, a thorough and complete visual scan of the piece of the lower 
CAM was done using a fluorescent microscope. Chick embryos were 
sacrificed by decapitation.   
2.24. Statistical Analysis  
Results were expressed as means ± SEM of the number of 
experiments. A p value of < 0.05 was considered statistically significant. 
Student’s t-test was used to detect the difference between the two values. 
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CHAPTER 3: RESULTS AND DISCUSSION 
Part I. Anti-breast cancer activity of Salinomycin 
3.1 Growth Inhibitory Effect of Salinomycin on MDA-MB-231, MCF-7 
and T47D Breast Cancer Cell Lines 
To examine the anticancer activity of Salinomycin on breast cancer 
cells, we first measured the effect of various concentrations of 
Salinomycin (1, 2.5, 5, 10, 25 and 50 µM) on the proliferation of three 
different breast cancer cell lines (MDA-MB-231, MCF-7 and T47D). The 
data obtained is summarized in figure 1. Our results show that exposure 
of the three cell lines to Salinomycin decreased cellular viability in 
concentration and in a time-dependent manner. However, the growth 
inhibitory effect of Salinomycin appears to be more pronounced in MCF-7 
and T47D than in MDA-MB-231. The IC50 (producing half-maximal 
inhibition) at 24 hours was approximately 40 µM for the MCF-7 and T47D 
(fig. 2 and 3) while the same concentration gave only about 35% inhibition 
of proliferation in the MDA-MB-231 cells (fig. 1). Following 48 hours of 
treatment, IC50 was 15 µM for the MCF-7 and T47D (fig. 2 and 3) and 
approximately 35 µM for the MDA-MB-231 cells. Maximal inhibition (90%, 
P<0.05) of cell growth was observed with 50µM for the MCF-7 and T47D 
cell lines. The same concentration gave approximately 70% inhibition of 
proliferation of the MDA-MB-231cell lines (fig.1). Taken together, our data 
show that Salinomycin inhibits cell growth of breast cancer cell lines in a 
concentration and time-dependent manner and that MCF-7 and T47D 
exhibit a greater sensitivity to Salinomycin compared to the MDA-MB-231 
cells.  
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Figure 1. Inhibition of Cellular Viability of MDA-M-231 Cells by 
Salinomycin. 
  
 
Figure 2. Inhibition of Cellular Viability of MCF-7 Cells by Salinomycin. 
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Figure 3. Inhibition of Cellular Viability of T47-D Cells by Salinomycin. 
 
 
 
Figure 4. Cell Viability of MDA-MB-231 Cells in Response to Various 
Concentrations of Salinomycin Using Trypan Blue Exclusion Dye Assay. 
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We next focused only on the highly proliferative and invasive 
Estrogen Receptor (ER)-negative, mutant p53 breast cancer cell line 
MDA-MB-231 to investigate the mechanism by which Salinomycin 
decreased cell viability. 
In order to distinguish between cell death and the possible growth 
arrest effects of Salinomycin, cell viability of the MDA-MB-231 cells was 
monitored by using the trypan blue exclusion dye assay at 24 and 48 
hours after the Salinomycin treatment. As it is shown in Figure 4, Trypan 
Blue Assay also showed a dose- and time-dependent decrease in viability 
in Salinomycin-treated cells when compared to the control cells.  
However, a closer look to the number of viable (Trypan Blue Negative) 
cells counted in each treatment, revealed that the number of cells after 
treatment with 2.5, 5 and 10 µM did not significantly change at 24 and 48 
hours  and moreover, was comparable to the number of cells counted at 
the day of treatment (Table 1) with a very low percentage of cell death 
(Trypan Blue Positive) suggesting that proliferation of the MDA-MB-231 at 
these concentrations is inhibited and cell death is minimal (Table 1) . 
Interestingly, at higher concentrations of Salinomycin (25 and 50 µM), the 
number of viable MDA-MB-231 cells showed a steady decline after 24 and 
48 hours indicative of cell death. The number of viable cells compared to 
the day of treatment, dropped to 58% and 42% at 25 µM and to 48 and 
28% at 50 µM.  
Comparative analysis of cell viability between CellTiter-Glo and 
Trypan Blue Exclusion assay shows that cell viability data obtained by 
CellTiter-Glo and trypan blue exclusion assays are not perfectly super-
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imposable (fig. 5 and 6). As a matter of fact, the same concentration of 
Salinomycin gave slightly different IC50 between Trypan Blue Exclusion 
and CellTiter-Glo assay. 
 
Salinomycin 
(µM) 
Dead cells (number and %)  
Viable cells (number and 
%)  
24 hours 48 hours 24 hours 48 hours 
Control 589 (1.0%)  2311 (2%) 
64122 
(100%)  
143055 
(100%)  
2.5 1078 (2.0%)  1444 (2.0%) 48822 (76%) 63688 (45%) 
5 1844 (4.0%)  2700 (4.0%) 46877 (73%) 55400 (39%) 
10 2244 (6%)  3244 (7%) 39322 (61%) 43844 (31%) 
25  4478 (17%)  6978 (27%) 23288 (36%) 19377 (41%) 
50  2156 (12%) 12089 (50%) 16244 (25%) 11333 (8%) 
  * Number of cells counted at the day of treatment (0h) approximately 
39000 
 
Table 1. Viability of MDA-MB-231 Cells in Response to Salinomycin 
Determined by Trypan Blue Exclusion Assay. 
 
  
 22 
 
 
 
Figure 5. Cell Viability of the MDA-MB-231 Cells in Response to 
Salinomycin After 24 Hours Determined by Trypan Blue Exclusion Dye 
and CellTiter-Glo Assays. 
 
 
Figure 6. Cell Viability of MDA-MB-231 Cells in Response to Salinomycin 
After 48 Hours Determined by Trypan Blue Exclusion Dye and CellTiter-
Glo Assays.  
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3.2 Salinomycin Induces Morphological Changes in MDA-MB-231 
Cells 
Light microscopy observation of Salinomycin-treated MDA-MB-231 
cells revealed morphological changes induced by this compound. As 
shown in figure 7, MDA-MB-231 cells treated with concentrations of 
Salinomycin 5, 10 and 25 µM, underwent morphological changes 
characterized by a loss of their epithelial morphology visible after 24 hours 
of treatment. These cells appeared dispersed and exhibited fibroblast-like 
morphology with filopodia-like extensions and central nuclei. However, the 
fibroblast-like morphology observed in  these cells is not due to  an 
epithelial-mesenchymal transition, since no changes in levels of vimentin 
and E.cadherin proteins was detected by a western blot analysis (fig. 8) 
and immunofluorescence (fig. 9). Interestingly, a subpopulation of MDA-
MB-231 cells treated with low concentration of Salinomycin exhibited a 
senescence-like phenotype characterized by cell size increase and 
flattening shape compared to the control cells (fig. 7 arrows). At higher 
concentrations of Salinomycin (25 and 50µM), cells appeared smaller and 
rounded, characteristic of cells undergoing apoptosis. Strikingly, lower 
concentrations of Salinomycin up to 10 µM did not lead to further change 
in cell morphology nor to cell density after 72 hours exposure to 
Salinomycin (fig 10). In contrast higher concentrations (25 and 50) led to 
fewer cells on the plate and further rounded cells. These morphological 
changes seem to be specific to MDA-MB-231 cells, since no obvious 
changes were observed in the MCF-7 and T47D cell lines.   
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Figure 7. Morphological Changes Observed in the MDA-MB 231 Cells 
After 24 Hours of Treatment with Various Concentration of Salinomycin. 
 
 
 
 
 
Figure  8. Western Blot Analysis of Vimentin and E-cadherin Expression in 
Salinomycin Treated MDA-MB-231 Cells. 
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Figure 9. Immunofluorescence Staining for Vimentin in Salinomycin 
Treated MDA-MB-231 Cells.  
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Figure 10. Morphological Changes Observed in the MDA-MB 231 Cells 
After 72 Hours of Treatment with Various Concentrations of Salinomycin. 
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3.3 Salinomycin Induces Apoptosis in MDA-MB-231 Cells  
Salinomycin was reported to mediate apoptosis in many human 
cancer cells [115]. Therefore, we investigated whether the observed 
inhibition of cell viability upon Salinomycin treatment in the MDA-MB-231 
cells was associated with the induction of apoptosis. Flow cytometry 
analysis of Annexin V and Propidium Iodide (PI) stain was used to 
determine the percentage of apoptotic cells induced by Salinomycin after 
24 hours of treatment. Treatment with 5 and 10 µM Salinomycin did not 
lead to a change in the early stage (Annexin V+/PI-) nor in the late stage 
apoptotic cells (Annexin V+/PI+)/necrotic cells suggesting the absence or 
minimal cell death in these populations (fig. 11). However, higher 
concentrations (25 µM) led to an increase in both early and late 
apoptotic/necrotic cell population.  
Immunofluorescence microscopy was also used to confirm 
apoptosis in the Salinomycin-treated cells. Fluorescence staining of 
Annexin V was detected only in cells treated with 25 µM of Salinomycin 
(fig. 3B, lower panel), while no Annexin V staining was detected at a 
concentration of 10 µM (fig. 12, middle panel) or lower concentrations, 
further confirming the absence of apoptosis in these cells. Interestingly, 
the proportion of dead cells detected by Trypan Blue Exclusion Assay at 
25 µM was higher than the proportion of apoptotic cells detected by flow 
cytometry suggesting that apoptosis might account only partly for the cell 
death induced by high concentrations of Salinomycin. 
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Figure 11. Salinomycin induced apoptosis in the MDA-MB-231 cells. 
Annexin V binding was carried out using Annexin V-FITC Detection Kit. 
 
 
 
Figure  12. Immunofluorescence Staining for Annexin V-FITC in 
Salinomycin Treated MDA-MB-231 Cells. 
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Apoptosis was further examined by measuring Caspase 3/7 
activation in MDA-MB-231 cells treated with low (10µM) or high 
concentrations (50µM) of Salinomycin after 24 and 48 hours of treatment. 
Consistent with Annexin V staining, Caspase 3/7 activation was detected 
in cells treated with 50µM but not in cells treated with 10µM (fig. 13). 
Furthermore, as figure 14 shows, PARP cleavage occurred only in cells 
treated with higher concentrations of Salinomycin (25 and 50µM), while no 
cleaved PARP is detectable at lower concentration of Salinomycin (5 and 
10µM). The lack of Caspase 3/7 activation and cleavage of PARP in MDA-
MB-231 suggest that the reduced cell viability observed in MDA-MB-231 
cells treated with low concentrations of Salinomycin (≤10µM) resulted from 
an inhibition of cell proliferation and was not caused by cell death.  
 
Figure 13. Stimulation of Caspase 3/7 Activity in MDA-MB-231 Cells After 
Exposure to Salinomycin (10 and 25 µM) for 24 and 48 Hours. 
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Figure 14. Western Blot Analysis Showing Dose-and Time-Dependent 
Induction of PARP Cleavage in Salinomycin Treated MDA-MB-231 Cells. 
* represents non-specific band  
 
 
3.4 Salinomycin Induces Growth Arrest in MDA-MB-231 Cells and 
Inhibited Colony Growth  
To confirm that low concentrations of Salinomycin induced growth 
inhibition of MDA-MB-231, cells were treated with DMSO or Salinomycin 
(2.5 and 5 µM) and kept in a culture for 6 days then cell viability was 
measured after 1, 3 and 6 days by counting viable cells using Trypan Blue 
Exclusion Assay. Figure 15 clearly shows that while DMSO treated MDA-
MB-231 cells continued to proliferate, Salinomycin-treated cells exhibited 
a strong inhibition of proliferation. Moreover, the inhibition of cellular 
proliferation induced by low concentrations of Salinomycin persisted even 
upon removal of the drug further indicating that, a low concentration of 
Salinomycin induces a permanent cell cycle arrest of the MDA-MB-231 
cells. These results along with the cell viability data strongly suggest that 
Salinomycin has a differential effect on the MDA-MB-231 cells depending 
on the concentration used. At low concentrations, Salinomycin inhibits 
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cellular proliferation without inducing cell death, while at high 
concentrations it exerts its effects by inducing apoptosis through activation 
of caspase 3/7 and PARP cleavage. 
 To further confirm the growth arrest potential of Salinomycin on 
MDA-MB-231 cells, we sought to determine if Salinomycin inhibits the 
growth of formed colonies. Figure 16 shows that the size of a control 
group of DMSO-treated colonies kept growing after three weeks 
compared to the size of the control colonies at two week; more large and 
medium size colonies are obtained in the three week plate, while fewer 
small colonies were counted, indicating that medium colonies became 
larger in size and smaller ones became medium sized colonies. 
Interestingly, the colony sizes counted in the three week Salinomycin-
treated plates were indistinguishable from those in the two week control 
DMSO-treated plates, indicating that Salinomycin was able to completely 
block the growth of the MDA-MB-231 colonies. This data further confirms 
the growth inhibitory effect of low concentrations of Salinomycin on the 
proliferation of MDA-MB-231 cells. 
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Figure 15. Inhibition of Proliferation by Salinomycin in MDA-MB-231 
Cells. 
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Figure 16. Induction of Growth Arrest by Salinomycin in MDA-MB-231 
Cells. 
 
3.5 Salinomycin Induced G2 Arrest and Senescence in MDA-MB-231 
Cells 
To examine the mechanism for Salinomycin-induced growth 
inhibition, cell cycle distribution was analyzed by flow cytometry. MDA-
MB-231 cells were treated with the indicated concentrations of 
Salinomycin (5, 10 and 25 µM) for 24 and 48 h.  
As shown in figure 17, the concentration of Salinomycin at 10 and 
25 µM caused an obvious G/2M arrest to the MDA-MB231 cells in a 
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concentration and time-dependent manner. The population of G2/M 
increased from 28% in DMSO-treated cells to 33 and 44% at 24 hours, 
respectively (fig. 17, upper panel). Similarly, the G2/M population 
increased from 22 to 43.6 and 49.67% at 48 hours, respectively (fig. 17, 
lower panel). Surprisingly, at lower concentration (2.5 and 5 µM), 
Salinomycin was found to induce a transient cell cycle arrest in G1 and 
G2/M over time. In fact, Salinomycin induced an accumulation of cells in 
G1 phase at 24 hours and successive accumulation in the G2 phase at 48 
hours post-treatment.  
To determine whether Salinomycin induced cell cycle arrest 
specifically at mitosis or G2 phase, we examined the phosphorylation 
status of Histone H3 (Ser 10). Histone H3 is phosphorylated at serine 10 
during mitosis by aurora kinase and the phosphorylation status of H3 is 
considered as a marker of mitosis [132]. We therefore, investigated the 
expression of p(ser10)H3 and found a time and dose-dependent decrease 
in the phosphorylation level of Histone H3 in response to the Salinomycin 
treatment (fig. 18, upper panel) . This result indicated that Salinomycin 
induced G2 arrest of MDA-MB231 cells. We also examined the expression 
of cyclin B1 in Salinomycin treated cells. An accumulation of cyclin B1 is 
well known to play an important role in G2/M transition. Knock-down of 
cyclin B1 with siRNA produces cell cycle arrest predominantly in the G2 
phase [133], while an upregulation of cyclin B1 invokes mitotic arrest 
[134]. We found that Salinomycin also decreased cyclin B1 level in a time- 
and dose-dependent manner (fig. 18. middle panel), further confirming 
that Salinomycin induced a cell cycle arrest in the G2 phase in MDA-MB-
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231 cells. However, a sensitive decrease of cyclin B1 began at higher 
concentrations of Salinomycin. 
G1 arrest observed at 24 hours with low concentrations of 
Salinomycin prompted us to examine the expression levels of cyclin D1 
protein involved in the control of the G1/S transition. It has been shown 
that overexpression of cyclin D1 shortens the G1 phase and occurs in 
many types of human cancers, whereas inhibition of cyclin D1 expression 
blocks G1-S transition [135-137]. As shown in Figure. 18 (lower panel), 
the level of cyclin D1 decreased upon treatment with Salinomycin in a 
time- and dose-dependent manner. Remarkably, no cyclin D1 protein was 
detected at 48 hours with a high concentration of Salinomycin.  
MDA-MB-231 cells treated with low concentrations of Salinomycin 
exhibited the behavior of senescent cells characterized by cell viability; 
metabolically active and permanently growth arrested. Therefore, we next 
determined whether the growth arrested MDA-MB-231 cells did indeed 
undergo senescence. It is well known that senescent cells express a 
senescence-associated β-galactosidase (SA-β-Gal), which is detected by 
incubating cells with X-gal at a pH of 6.0. Our results show that 30% of 
Salinomycin-treated cells expressed SA-β-galactosidase (fig. 19), 
indicating that induction of senescence contributes to the inhibitory effect 
of Salinomycin on the proliferation of MDA-MB-231 cells.  
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Figure 17. Flow Cytometry Analysis of Salinomycin-induced G2 Cell-Cycle 
Arrest in MDA-MB-231 Cells. 
 
 
 
 
Figure 18. Western Blot Analysis of p(ser10) histone H3, cyclin B1 and 
cyclinD1 Expression in Salinomycin Treated MDA-MB-231. 
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Figure 19. Salinomycin Induced Senescence in MDA-MB-231 Cells After 
Incubated with 5 µM Salinomycin for 96 Hours and Stained for SA-β-
Galactosidase Activity. 
 
3.6 Salinomycin Induced activation of γH2AX, a Marker of Double 
Strand Breaks, in MDA-MB 231 Cells 
Several studies showed that cells can undergo premature 
senescence in response to exposure to oxidative or genotoxic stresses 
that cause DNA damage. Interestingly, Salinomycin was shown to induce 
an elevation in the intracellular reactive oxygen species (ROS) levels and 
mitochondrial membrane depolarization [118]. Moreover, Salinomycin was 
also shown to induce DNA damage in MCF-7 and Hs578T human breast 
cancer cells [121, 122]. Therefore, we sought to investigate whether 
Salinomycin induced DNA damage in MDA-MB-231 cells as well. For this 
purpose, MDA-MB-231 cells were cultured for 6, 24 and 48 hours in 
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complete media containing either DMSO or an increasing concentration of 
Salinomycin (5-50 µM). DNA damage was determined by measuring the 
levels of phosphorylated H2AX (γH2AX) in non-treated and Salinomycin-
treated cells. Western blot analysis revealed a concentration- and time-
dependent increase in the levels of γH2AX (fig. 20) in the MDA-MB-231 
cells in response to the Salinomycin treatment, indicating an accumulation 
of double strand breaks in these cells. An increase in DNA damage was 
also assessed by immunofluorescence staining of γH2AX in cells treated 
with 10 and 50µM Salinomycin for 24 hours. Figure 21 clearly shows a 
concentration-dependent increase of γH2AX foci in response to 
Salinomycin. Since the activation of γH2AX occurs even at concentrations 
of Salinomycin that do not lead to cell death (5 and 10µM), this rules out 
the possibility that the resulting DNA damage is a consequence of DNA 
fragmentation resulting from Caspase 3/7 activation and further confirming 
the potential of this drug to induce double strand DNA breaks in a 
concentration-dependent manner.  
 
 
 
Figure 20. Western Blot Analysis of Phosphor-H2AX (Ser 139) in MDA-
MB-231 Cells Treated for 6, 24 and 48 Hours with DMSO or Indicated 
Concentrations of Salinomycin. 
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Figure 21. Immunofluorescence Staining for γH2AX in Salinomycin 
Treated MDA-MB-231cells. 
 
3.7 Salinomycin Induced p53-Independent Upregulation of p21waf/cip 
in Growth Arrested MDA-MB-231 Cells 
Because p21 protein has been reported to inhibit growth and 
apoptosis and mediate senescence, we investigated whether the growth 
inhibition and senescence mediated by Salinomycin was associated with 
an induction of p21. MDA-MB-231 cells were cultured in the presence of 
DMSO or an increasing concentration of Salinomycin for 6, 24 and 48 
hours. Western blot analysis of p21 level in Salinomycin-treated cells with 
concentrations causing growth arrest and senescence showed an 
increase in the protein level detected starting from 6 hours of treatment 
(fig. 22). At the concentrations of Salinomycin causing cell death, we 
observed that while a concentration of 50 µM caused a quick decrease of 
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p21 level detected as early as 6 hours, a concentration of 25 µM, 
however, led to a transient increase of p21 at 6 hours followed by a 
decline in the protein level at 24 and 48 hours (fig. 22).  These 
observations were further confirmed by immunofluorescence staining of 
p21 in cells treated with 10 µM Salinomycin (fig. 23). As expected, no 
induction of mutant p53 in the MDA-MB-231 cells was observed, thus 
strongly suggesting that the induction of p21 by Salinomycin in MDA-MB-
231 cells occurred independently of p53 function.  
The levels of another CDK inhibitor, p27 was also determined at 24 
and 48 hours post-treatment. As it is shown in figure 24, the level of p27 
showed a concentration and time-dependent decrease in MDA-MB-231 
cells.  
 
 
Figure 22. Western Blot Analysis of p21 Expression in Salinomycin 
Treated MD-MB 231 Cells. 
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Figure 23. Immunofluorescence Staining for p21 in Salinomycin Treated 
MDA-MB-231Cells. DAPI is used as a nuclear stain. 
 
 
 
 
Figure 24. Western Blotting Analysis of p27 Expression in MDA-MB-231 
Cells upon Salinomycin Treatment. 
 
3.8 Salinomycin Induced Downregulation of Survivin Expression in 
MDA-MB-231 Cells 
Survivin, a member of the inhibitor of apoptosis protein (IAP) family, 
plays an important role in both the regulation of cell cycle and the 
inhibition of apoptosis. However, a decrease in survivin levels has been 
shown to sensitize cells to apoptosis. Therefore, we examined the 
possible involvement of survivin in cell cycle arrest and apoptosis as 
triggered by Salinomycin. Toward this end, we analyzed, by Western 
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blotting, the expression of survivin in response to various concentrations 
of Salinomycin after 24 and 48 hours of treatment. As shown in figure 25, 
while low concentrations of Salinomycin led to no obvious change in 
survivin expression, higher concentrations (25 and 50 µM), caused a 
drastic decrease in survivin protein level at 24 and 48 hours, consequently 
sensitizing MD-MB-231 to cell death. The persistence of survivin 
expression at concentrations causing growth arrest and senescence could 
also account for the resistance to cell death of Salinomycin-treated cells.  
 
 
Figure  25. Western Blot Analysis of Survivin Expression in Salinomycin-
Treated MDA-MB 231 Cells. 
 
3.9 Salinomycin Induced Hyperacetylation of Histone H3 and H4 in 
the MDA-MB-231 Cells 
The expression of p21 and increased histone hyperacetylation 
have been previously linked to apoptosis, growth arrest and cellular 
senescence. Therefore, we examined the acetylation profile of Histone H3 
and H4 in MDA-MB-231 cells at 6, 24 and 48 hours with increasing 
concentrations of Salinomycin. In figure 26, time course analysis showed 
a gradual increase in acetylated Histones, H3 and H4. A marked overall 
increase in the acetylation status of histone H3 and H4 was also detected 
by immunofluorescence staining (fig. 27). Altogether, these results show 
that Salinomycin induces acetylation of Histone H3 and H4. 
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Figure 26. Western Blot Analysis of Ac-H3 and Ac-H4 Expression in 
Salinomycin Treated MDA-MB 231 Cells. β-actin was used as loading 
control. 
 
 
 
Figure  27. Immunofluorescence Staining of Ac-H3 and Ac-H4 in MDA-
MB-231 Cells Treated with 10 and 25 µM Salinomycin for 24 hours. DAPI 
was used as a nuclear stain. 
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3.10 Combination of Salinomycin with Frondoside A or with 4-
Hydroxy-Tamoxifen Enhanced Cell Death and Activation of 
Caspase3/7 
Recently, frondoside A (Fr), a triterpenoid glycoside isolated from 
the sea cucumber, Cucumaria frondosa, has been shown to inhibit 
survival, migration, and invasion of MDA-MB-231 cells [138]. In vivo, 
frondoside A strongly decreased the growth of MDA-MB-231 tumor 
xenografts in athymic mice, without precipitating significant toxic side-
effects. Although frondoside A is not used as an anti-cancer drug, we 
decided to investigate whether Salinomycin could sensitize MDA-MB-231 
cells to this compound. We have chosen to use 1µM of frondoside A, a 
concentration that induces 30% inhibition of cellular viability. Remarkably, 
frondoside A potentiated the growth inhibitory effect of different 
concentrations of Salinomycin (fig. 28).   
We next examined the efficacy of Salinomycin (2.5-50 µM) in 
combination with 4-Hydroxy-Tamoxifen (20 µM), the active metabolite of 
tamoxifen, the breast cancer drug, in MCF-7 cells. Combined treatment 
caused a significantly greater inhibition in cellular viability than treatment 
with either drug alone (fig. 29) after 48 hours of treatment. Moreover, a 
combination of Salinomycin with 4-Hydroxy-Tamoxifen significantly 
increased the activation of Caspase 3/7, suggesting that apoptosis is 
higher compared with treatment with either drug alone (fig. 30). 
  
  
 54 
 
 
Figure 28. Salinomycin Enhanced Cell Death Induced by Frondoside A in 
MDA-MB-231 Cells. 
 
 
Figure 29. Salinomycin Enhanced Cell Death Induced by 4 Hydroxy-
Tamoxifen in MCF-7 Cells. 
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Figure 30. Salinomycin Induced Synergistic Apoptosis Against MCF-7 
Cells. Fr represents frondoside A, Salino represents Salinomycin and 4-
HT represents 4-Hydroxy-Tamoxifen. 
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DISCUSSION 
  
Common cancer treatment drugs aim at inducing cell death and 
apoptosis, which are considered prerequisites for preventing malignant 
cell growth. Several studies have demonstrated that cellular senescence 
can occur in vivo and may provide a critical barrier for cancer 
development and cancer progression [139]. In fact, treatment of cancer 
cell lines with different chemotherapeutic drugs induces irreversible 
growth arrest associated with senescence like-phenotype [140, 141]. 
Indeed, induced-senescence appears to be a promising alternative 
strategy for cancer treatment. 
Our present work shows that (1) Salinomycin significantly 
decreased viability of the wild-type p53 MCF-7 and T47D as well as 
mutant p53 MDA-MB-231 human breast cancer cell lines in concentration 
and time–dependent manners, and that (2) MDA-MB-231 cells respond 
differently to low and high concentrations of Salinomycin. Our results 
demonstrate that high concentrations of Salinomycin (25 and 50 µM) 
induce G2 arrest, downregulation of survivin and activation of the 
apoptotic signaling pathway resulting in the activation of Caspase 3/7 and 
PARP cleavage. This finding is in agreement with previous reports 
demonstrating that the anti-cancer effect of Salinomycin on different 
cancer cell lines was due to its apoptosis-inducing activity [115, 118, 123, 
142]. Interestingly, our results show for the first time that low 
concentrations of Salinomycin (≤10µM) induce senescence in MDA-MB-
231 cells. We found that Salinomycin-treated MDA-MB-231 cells exhibited 
markers of senescence including SA-β-galactosidase activity, changes in 
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morphology, cell cycle arrest, Histone H3 and H4 hyperacetylation and 
elevated expression of the cyclin-dependent kinase inhibitor, p21. We also 
report that Salinomycin enhanced the killing of the MCF-7 and MDA-MB-
231 cells by chemotherapeutic agents, 4-Hydroxy-Tamoxifen and 
frondoside A, respectively. 
We showed that data on the cell viability of MDA-MB-231 
determined by CellTiter-Glo and Trypan Blue Exclusion were not super-
imposable even though they follow the same pattern i.e. growth inhibition 
at lower concentrations and cell death at higher concentrations. CellTiter-
Glo Assay which is based on quantification of the ATP present showed 
less effect on the viability of the MDA-MB-231 compared to the Trypan 
Blue Exclusion Assay when the same concentration was used.  
Interestingly, it has been reported that DNA-damaging agents such as 
etoposide and temozolomide induce an ATP surge in cancer cells [143], 
which explains the differences observed between CellTiter-Glo and 
Trypan Blue Exclusion Assay in Salinomycin-treated MDA-MBA-231 cells.  
In our study, we observed that at a concentration of 2.5 and 5 µM, 
Salinomycin induced a G1 arrest at 24 hours and G2 arrest at 48 hours 
post-treatment. Earlier reports have shown that low concentrations of 2.5 
and 5 µM of Salinomycin also induced a G1 arrest in the MCF-7 and 
Hs578T breast cancer cells after 24 hours of treatment [122, 123] which is 
in agreement with our data on the MDA-MB-231 cells. However, no further 
concentrations or time points were tested.  Cyclin D1, a cyclin required for 
G1 to S transition, was found to be reduced upon Salinomycin treatment 
and could be the main cause for the G1 block. Our data also suggested 
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that cell cycle arrest at the G2 phase might be mediated by the reduction 
of cyclin B1. Moreover, the level of cyclin B1 at 5 µM Salinomycin seemed 
to decrease at later times than cyclin D1 decreased. Interestingly, 
Curcumin was also shown to induce a successive G1/S arrest at earlier 
times and G2/M phase arrest at later time point in HOS cells [144]. The 
exact mechanism by which cells undergo a transient G1 arrest followed by 
a G2 arrest remains unclear. Our data also showed, for the first time, that 
Salinomycin at higher concentration induced a robust G2 arrest confirmed 
by cyclin B1 decrease and p(ser10) Histone H3. The cell cycle arrest data 
is in agreement with the growth inhibition data shown by cell viability (fig 1, 
5,6, 15) and colony growth assay (fig. 16). Interestingly, we found that the 
CDK inhibitor p27, also a marker of G1 arrest, was downregulated during 
the transient G1 arrest observed at 5 µM. This is not surprising as a report 
by Yongxian and Miskimins showed that G1 arrest in MDA-MB-231 breast 
cancer cells treated with metformin involves down regulation of cyclin D1 
and requires p27 or p21 [145].  
Inhibitor of Apoptosis Proteins (IAPs), which includes survivin, 
represents a family of anti-apoptotic proteins that bind and inactivate 
Caspase 3, 7 and 9 [146-148] and can modulate cell division and cell 
cycle progression [149]. Survivin has been shown to be highly expressed 
in most cancers, where it functions as an inhibitor of apoptosis. In breast 
cancer, overexpressed survivin was shown to protect cells against 
apoptosis induced by chemotherapeutic agents, such as Etoposide [150]. 
In consideration of the role of survivin as a custodian of cancer cell 
survival, our results suggest that Salinomycin at high concentration might 
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exert its cytotoxic anti-cancer effects at least partly via the down-
regulation of survivin. 
Senescent cells are known to remain viable and metabolically 
active, but are permanently growth arrested [151]. Growth arrest is 
achieved and maintained in either G1 or G2/M stage of cell cycle, at least 
through overexpression of specific cyclin-dependent kinase inhibitors such 
as p16, p21 and p27 [139] [152-154]. Schwarze et al have previously 
shown that p21 is more important in cell cycle arrest that is associated 
with early senescence, while p16 appears to be important for maintaining 
the senescence phenotype [152]. Senescence is triggered by DNA 
damage to cells which respond via the induction of a group of genes 
responsible for the development of the senescence phenotype [155].  The 
decision of the cell to undergo either apoptosis or senescence is 
dependent, at least in part, upon the magnitude of DNA damage caused 
to cancer cells. Low levels of DNA damage may induce senescence 
without activating the apoptotic pathway. Several studies reported that 
many senescence inducing drugs generate DNA damage. In fact, 
treatment of prostate cancer cells with high doses of doxorubicin, a DNA-
damage inducing chemotherapeutic drug, leads to apoptosis, while a 
lower dose of doxorubicin induces senescence [156]. Furthermore, 
doxorubicin was shown to induce senescence in numerous cancer cell 
lines, including those lacking p53 [157] .The same observation was made 
when cisplatin [158], hydroxyurea [159] or bromodeoxy uridine [160] were 
used. 
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The expression of the cyclin-dependent kinase inhibitor p21 has 
been implicated in chemotherapy induced cell cycle arrest in various 
human cancers [152, 153, 161-163]. The contribution of p21 to cellular 
senescence has been demonstrated by numerous studies [152-154]. In 
fact, p21 has been found to be upregulated in senescent cells. Moreover, 
forced overexpression of p21 was shown to be sufficient to induce cell 
cycle arrest, and premature senescence in wild-type and mutant p53 cells 
[155]. In line with this data, we reported that Salinomycin at concentrations 
of ≤ 10 µM is able to induce maintained upregulation of p21 expression in 
the MDA-MB-231 cells. Based on these data, we propose that induction of 
senescence in Salinomycin-treated MDA-MB-231 breast cancer cells is 
mediated, at least, partly through a p53-independent upregulation of p21 
protein and does not involve p27 since, its expression decreased in a 
time- and dose dependent manner (fig. 24).   
It has also been reported that cellular senescence is associated 
with modifications in chromatin structure [156, 157]. Histone 
hyperacetylation has been directly linked to the upregulation of p21 and 
this activation can also occur independently of p53 [39]. Our data showed 
that Salinomycin induced Histone H3 and H4 hyperacetylation. We have 
also found that histone hyperacetylation correlated with a p53-
independent upregulation of p21 expression and growth inhibition in the 
MDA-MB-231 cells. Our data suggest that Histone H3 and H4 
hyperacetylation could be one of the mechanisms through which 
Salinomycin exerts its anti-cancer activity, at least, in breast cancer. 
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Recent studies reported that Salinomycin potentiates the anti-
cancer activity of several DNA damage-inducing chemotherapeutic drugs 
[121] as well as sensitizes cancer cells to radiation [122].  Salinomycin 
was also shown to sensitize cancer cells to inhibitors of DNA replication 
[120] and to antimitotic drugs [123]. Consistent with these reports, our 
results show that Salinomycin indeed potentiates the anti-cancer activity 
of two other drugs, namely frondoside A and the anti-estrogen 4-Hydroxy-
Tamoxifen in MDA-MB-231 and MCF-7 respectively. 
 In summary, our study is consistent with the model shown in figure 
31, in which treatment with Salinomycin induces double strand breaks, 
revealed by an accumulation of γH2AX. The magnitude of DNA damage, 
which depends on the concentration of Salinomycin, determines the 
response of the cells to this damage. We propose that the presence of 
large amounts of DNA damage induced by high concentrations of 
Salinomycin, MDA-MB-231 cells respond by triggering the apoptotic 
signaling pathway through activation of Caspase 3/7 and cleavage of 
PARP.  In contrast, limited DNA damage caused by low concentrations of 
Salinomycin triggers a rapid program of senescence which is mediated, at 
least partly, through hyperacetylation of Histone H3 and H4 which 
subsequently results in the upregulation of p21 expression.  
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Figure 31. Hypothetic Model for the Differential Effect of Salinomycin in 
MDA-MB-231 Breast Cancer Cells. 
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CHAPTER 3: RESULTS AND DISCUSSION  
Part II. Anti-Tumor Growth and Anti-Metastatic Activity of Origanum 
majorana Extract on the Triple Negative Breast Cancer 
3.12 O. majorana Extract Inhibited the Viability of the MDA-MB-231 
Breast Cancer Cells 
To examine the anticancer activity of Origanum majorana extract 
(OME) on breast cancer cells, we first measured the effect of various 
concentrations of the extract (0, 50, 150, 300, 450 and 600 µg/mL) on the 
proliferation of the MDA-MB-231 breast cancer cell line (fig. 34). Our 
results show that exposure of the MDA-MB-231 to OME decreased 
cellular viability in a concentration- and a time-dependent manner. The 
IC50 (producing half-maximal inhibition) was approximately 350 µg/mL at 
24 hours and 400 µg/mL at 48 hours treatment. Observation of the OME-
treated MDA-MB231 cells under light microscopy also revealed that the 
number of cells decreased when the concentration increased. 
Furthermore, as shown in figure 33, light microscopy observation of MDA-
MB231 cells treated with concentrations of 150, 300 and 450 and 600 
µg/mL OME, underwent morphological changes characterized by a loss of 
their epithelial morphology visible after 24 hours of treatment. Echinoid 
spikes and cellular rounding, characteristics of apoptotic cells were also 
observed. 
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Figure  32. Inhibition of Cell Viability of MDA-MB-231 Cells by O. 
majorana Extract. 
 
 
 
Figure   33 . Micrograph of MDA-MB-231 Cells After 24 Hours Incubation 
with Various Concentrations of OME.  
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3.13 O. majorana Extract Lead to Mitotic Arrest and Apoptosis in 
MDA-MB-231 Cells 
The ability of an anticancer drug to affect cell cycle distribution can 
provide information regarding its cytotoxic mechanism(s) of action. For 
this reason, we investigated the effect of OME on cell cycle distribution 
using flow cytometry. MDA-MB 231 cells were treated with the indicated 
concentration of O. majorana for 24 hours and subjected to cell cycle 
analysis. At a concentration of 150 µg/mL, OME caused an obvious G/2M 
arrest of these cells (fig. 34). Indeed, the population of G2/M increased 
significantly from 23 to 51.7% as the concentration of the OME increased 
to 150 µg/mL, indicating that OME-treated MDA-MB-231 cells were 
arrested in the G2/M phase. A slight increase in the sub-G1 population 
(6.2%) was also observed by these concentrations indicating that a small 
population of OME-treated MDA-MB-231 cells is undergoing cell death. 
Interestingly, at higher concentrations of OME, flow cytometry analysis 
revealed a dramatic increase in the apoptotic population (sub-G1 peak) 
rising from 0.9% in the control group to 48.4% and 56.7% in cells treated 
with 600 and 450 µg/mL, respectively (fg. 34). 
To determine whether OME specifically induced cell cycle arrest at 
mitosis or the G2 phase, we examined the phosphorylation status of 
Histone H3 (Ser 10). Histone H3 is phosphorylated at serine 10 during 
mitosis by aurora kinase and the phosphorylation status of H3 is 
considered a marker of mitosis [132]. We therefore, investigated the 
expression of p(ser10)H3 and found that treatments 150 and 300 µg/mL 
of O. majorana significantly increased the phosphorylation level of Histone 
 42 
 
H3 (fig. 35, upper panel). This result indicates that OME induces mitotic 
arrest of MDA-MB231 cells. Next, we investigated the mechanism of 
OME-induced mitotic arrest. Accumulation of cyclin B1 is well known to 
play an important role in G2/M transition. Knock-down of cyclin B1 with 
siRNA produces cell cycle arrest predominantly in the G2 phase [133], 
while an upregulation of cyclin B1 invokes mitotic arrest [134]. We, 
therefore, investigated the protein level of cyclin B1 in OME-treated MDA-
MB-231 cells. We found that treatment with these concentrations of OME 
leading to mitotic arrest, caused also an increase of cyclin B1 protein in 
MDA-MB-231 cells (fig. 35, lower panel), suggesting that cyclin B1 
accumulation might play a crucial role in OM triggered mitotic arrest. 
Taken together, our findings reveal a differential concentration effect of 
OME on cell cycle progression of MDA-MB 231 cells. Whereas, lower 
concentrations of OME (150 and 300 µg/mL) induced a major mitotic 
arrest with a slight increase in the apoptotic population, higher 
concentrations (450 and 600 µg/mL) induced massive cell death by 
apoptosis. The reduced cell viability observed in MDA-MB231 cells treated 
with low concentrations of OME, is possibly due to a large extent to an 
inhibition of cell proliferation rather than to cell death. 
  
 41 
 
 
Figure  34. Flow Cytometry Analysis Showing a G2/M Cell Cycle Arrest 
Induced by O. majorana Extract in MDA-MB-231 Cells. 
 
 
 
Figure  32 . 42Western Blot Analysis of Phosphor(ser10)-H3, and Cyclin 
B1 in OME Treated MDA-MB231 Cells. 
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Apoptosis in OME-treated MDA-MB-231 cells was further examined 
by measuring Caspase 3/7 activation in MDA-MB 231 cells treated with 
various concentrations (300, 450 and 600 µg/mL) of OME after 24 hours 
of treatment. A concentration- and time-dependent activation of caspase 
3/7 was detected in treated cells (fig 36). Interestingly, cleavage of the 
poly(ADP-ribose) polymerase (PARP) occurred only in cells treated with 
higher (450 and 600 µg/mL), but not at lower concentrations (150 and 300 
µg/ml) of OME (fig. 37). It is worth mentioning that at these lower 
concentrations of OME, only a low apoptotic induction rate was observed 
despite the detection of Caspase 3/7 activation. 
 
Figure 36. Stimulation of Caspase 3/7 Activity in OME Treated in MDA-
MB-231 Cells. 
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Figure 37. Concentration-Dependent Induction of PARP Cleavage in OME 
Treated MDA-MB231 Cells. 
 
3.14 Concentration-Dependent Regulation of Survivin Expression by 
O. majorana Extract 
Survivin, a member of the inhibitor of apoptosis protein (IAP) family, 
plays an important role in both the regulation of cell cycle and the 
inhibition of apoptosis. Survivin levels increase in the G2/M phase 
conferring resistance to apoptosis to the G2/M arrested cells. However, a 
decrease in survivin levels sensitizes the cells to apoptosis. Several 
studies have reported that survivin exerts its negative effect on apoptosis 
by inhibiting the activity of Caspase 3, 7 and 9. Therefore, we examined 
the possible involvement of survivin in cell cycle arrest and apoptosis 
triggered by OME. We analyzed, by Western blotting, the expression of 
survivin in response to various concentrations of OME after 24 hours of 
treatment. Interestingly, we observed a differential concentration-effect of 
OME on survivin expression in the MDA-MB-231 cells (fig. 38). We found 
that low concentrations of OME led to a substantial increase in the level of 
survivin, while higher concentrations caused a drastic decrease of survivin 
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(99%). Based on these results, we concluded that OME exerts a 
concentration-dependent effect on MDA-MB-231 cells. Low 
concentrations of OME induced a mitotically arrested cells accompanied 
by survivin upregulation which, in turn, conferred resistance to cell death 
to this population of cells, probably by inhibiting the activity of Caspase 3/7 
which was monitored by the absence of PARP cleavage at these 
concentrations. Treatment of MDA-MB-231 cells with higher 
concentrations of OME caused a dramatic decrease in survivin expression 
and consequently sensitized MD-MB-231 cells to apoptosis. 
  
 
 
Figure  38. Western Blot Analysis Showing A differential Effect on Survivin 
Expression by Different Concentrations of OME in MDA-MB-231 Cells. 
 
3.15 O. majorana Extract Activates the Extrinsic Pathway for 
Apoptosis via an Upregulation of TNF-α and Activation of Caspase 8 
Having shown that OME induces the activation of the effector 
Caspases 3/7, we looked at the activity of the initiator caspases of the 
extrinsic and intrinsic cell death pathway, namely Caspase 8 and Caspase 
9, respectively. Surprisingly, no Caspase 9 activation was detected in 
 42 
 
response to various concentrations of OME after 24 hours of treatment (fig 
39). On the other hand, caspase 8 activity increased in a concentration-
dependent manner in response to OME treatment (fig 39). This result 
demonstrates that the apoptotic effect of the extract on MDA-MB-231 is 
dependent on caspase 8 activity, which implicates only the extrinsic cell 
death pathway since no caspase 9 activation was observed. After showing 
that the extrinsic cell death pathway is implicated in OME-dependent 
apoptosis, we were then interested in determining how this pathway is 
activated by OME. We determined the changes in the expression level of 
the Tumor Necrosis Factor Alpha (TNF-α) in response to OME after 24 
hours of treatment. Western blot analysis revealed a clear increase in the 
level of TNFα in MDA-MB-231 cells in response to OME treatment (fig. 
40). The upregulation of TNF-α was further confirmed by 
immunofluorescence assay (fig 41). Even though we have shown that 
OME exerts its effect via the activation of the extrinsic pathway of cell 
death, we cannot rule out, at this stage, the possibility of OME-dependent 
apoptosis could also be triggered by another mechanism. 
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Figure  39. O. majorana Induced Apoptosis by Activation of Caspase 8 
and but not Caspase 9 in MDA-MB-231 Cells. 
  
 
 
Figure  40. Western Blot Analysis Showing An increase in Cellular TNF-α 
Protein in the MDA-MB-231 Cells Treated with OME. 
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Figure  41. Immunofluorescence Staining for TNF-α in OME Treated 
MDA-MB- 231 Cells. 
 
3.16 O. majorana Lead to Depletion of Mutant p53 in MDA-MB-231 
and Upregulation of p21WAF1/CIP1 
Next, we tested the effect of OME on the expression of the tumor 
suppressor p53 in MDA-MB-231. Toward this aim, cells were treated with 
various concentrations of OME and the protein level of the mutant p53 
was determined. We found that low concentrations of 150 and 300 µg/mL 
of OME led to a slight increase in the protein level of mutant p53 (fig. 42, 
upper panel). Most importantly, Western blotting analysis revealed 
apoptotic concentrations (450 and 600 µg/mL of OME) lead to almost 
complete depletion of mutant p53 in MDA-MB-231 cells. This result is a 
potentially important finding because of the role of mutant p53 protein in 
human cancers. Because mutant p53 renders cancer cells more resistant 
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to anti-cancer drugs, abolishing mutant p53 may therefore offer a 
promising approach for cancer prevention and therapy. 
Because p21 protein has been reported to inhibit growth and 
apoptosis, we investigated whether the growth inhibition mediated by low 
concentrations (150 and 300 µg/mL of OME) was also associated with an 
induction of p21. Western blotting showed an upregulation of p21 protein 
with at least 2.5 fold increases in cells treated with low concentrations of 
OME, while little or no effect on p21 expression was observed with higher 
concentrations of OME (fig. 42, lower panel). Based on that, we can 
postulate that p21 upregulation contributes, at least partially, to the cell 
cycle arrest observed with lower concentrations, while it has little or no 
role in cell death occurring at higher concentrations of OME. 
  
.  
Figure  42. Western Blot Analysis Showing Expression Levels of Mutant 
p53 and p21 in O. majorana Treated MDA-MB-231 Cells. 
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3.17 O. majorana Extract Induced Hyperacetylation of Histone H3 and 
H4 in the MDA-MB 231 Cells 
Previously, expression of p21 and increased histone 
hyperacetylation has been linked to apoptosis and to growth arrest. 
Therefore, we examined the acetylation profile of histone H3 and H4 in 
MDA-MB-231 in response to treatment for 24 hours to increasing 
concentrations of OME. As shown in figure 43, the time course analysis 
showed a gradual increase in acetylated histones, H3 and H4. A marked 
overall increase in the acetylation status of Histone H3 and H4 was also 
detected by immunofluorescence staining (fig 44). Altogether, these 
results showed that OME induced hyperacetylation of Histone H3 and H4. 
 
 
Figure 43. Western Blot Analysis Showing Protein Levels of Ac-H3 and 
Ac-H4, Extracted from OME Treated Cells. β-actin was used as loading 
control. 
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Figure 44. Immunofluorescence Staining of Ac-H3 and Ac-H4 in MDA-
MB231 Cells Treated with OME for 24 Hours. DAPI was used as a nuclear 
stain. 
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3.18 O. majorana Induced Activation of γH2AX, a Marker of Double 
Strand Breaks, in MDA-MB-231 Cells 
We sought to investigate whether OME induced DNA damage in 
MDA-MB-231 cells. For this purpose, MDA-MB 231 cells were cultured for 
6 and 24 hours in a complete media containing either ethanol (control) or 
increasing concentrations of OME (75, 150, 300, 450 and 600 µg/mL). 
DNA damage was determined by measuring the levels of phosphorylated 
H2AX (γH2AX) after 6 and 24 hours of treatment of the MDA-MB-231 cells 
with OME. Western blot analysis revealed a time-and a concentration-
dependent increase in the levels of γH2AX in response to OME treatment 
(fig 45), indicating an accumulation of double strand breaks in these cells. 
The increase in DNA damage was also assessed by immunofluorescence 
staining of γH2AX in cells treated with 150, 300 and 450 µg/mL OME for 
24 hours. Figure 47 clearly shows a concentration-dependent increase of 
γH2AX foci in response to OME. Since the activation of γH2AX occurred 
as early as 6 hours, a time in which no cell death or Caspase 3/7 
activation was observed (fig. 46), this rules out the possibility that the 
resulting DNA damage is a consequence of DNA fragmentation resulting 
from caspases' activities and further confirms the potential of this OME 
extract to induce double strand DNA breaks in a concentration-dependent 
manner. 
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Figure  45. Western Blot Analysis of Phosphor-H2AX (Ser 139) in MDA-
MB231 Cells Exposed to OME. 
 
 
 
Figure  46. Immunofluorescence Staining for γH2AX in OME Treated 
MDA-MB 231 Cells. 
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Figure  47. Caspase 3/7 Activation in OME Treated MDA-MB-231 Cells 
After 6 Hours. 
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3.19 O. majorana Inhibited Colony Growth of MDA-MB-231 
To further confirm the inhibitory potential of O. majorana on MDA-
MB 231 cells, we sought to determine if OME could inhibit the further 
growth of already formed MDA-MB-231 colonies. For this purpose, MDA-
MB-231 cells were first allowed to grow and form visible colonies in the 
absence of treatment. After 14 days of growth, colonies were incubated 
with ethanol as a control, and with OME, and allowed to grow for one 
more week. Figure 48 shows that the size of the ethanol-treated (control) 
colonies kept growing compared to the size of the two week colonies; 
more large colonies were obtained in the three week plate, while fewer 
small colonies were counted, indicating that small colonies became larger 
in size. Interestingly, OM treated colonies showed regression in colony 
size compared to the two week colonies. In OM-treated plates, the 
number of large size colonies counted was fewer than that obtained in the 
two week plate, while the number of small colonies was significantly 
greater, suggesting size regression in the large colony induced by OME. 
This result along with the viability and flow cytometry data confirm the anti-
cancer effect of OME on triple negative mutant p53 MDA-MB-231 breast 
cancer cells. 
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.  
Figure 48. Inhibition of Colony Growth by O. majorana Extract. 
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3.20 O. majorana Attenuated the Migration Ability of the MDA-MB-231 
Breast Cancer Cells 
As cell migration plays a crucial role in tumor metastasis, we 
sought to investigate whether OME affects the migration behavior of MDA-
MB-231 cells. We first measured the migration ability of these cells by 
using a wound-healing migration assay. For this purpose, we performed 
the test with concentrations of OME and periods of treatment that were 
previously shown to be non-cytotoxic to the MDA-MB-231.  As shown in 
figure 49, OME treatment significantly inhibited wound healing cellular 
migration of MDA-MB-231 cells in a concentration-dependent manner. 
The ability of OME to inhibit the migration of MDA-MB-231 cells was also 
measured by using the Boyden Chamber Transwell Assay. For this 
purpose, MDA-MB-231 cells were seeded in the upper wells with or 
without 300 µg/mL OME.  As shown in Figure 51 and 52, the number of 
OME-treated cells that migrated to the lower chamber, after 6 hours of 
treatment, was significantly reduced approximately three fold compared to 
the number of control cells. Cell viability of the OME-treated cells at the 
concentrations and time tested was not affected (fig. 50) thus confirming 
that the inhibitory effect on the MDA-MB-231 cells motility was not due to 
the cytotoxic effect of OME. Taken together this confirms the inhibitory 
effect of OME on the migration potential of MDA-MB-231 cells. 
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Figure 49. Wound Healing Assay Showing that OME Inhibited the 
Migration of MDA-MB-231 Breast Cancer Cells in Dose-Dependent 
Manner. 
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Figure  50. Cell Viability After Incubation of MDA-MB-231 Cells with OME 
For 10 Hours. 
 
 
 
Figure 51. Boyden Chamber Transwell Assay Indicating that OME 
inhibited the Migration of MDA-MB-231 Cells. 
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Figure 52. Quantification of Migrated MDA-MB-231 Cells. 
 
3.21 O. majorana Promoted Cell-Cell Aggregation and Induced E-
Cadherin Upregulation in MDA-MB-231 Cells 
Lost capacity for homotypic adherence is also associated with 
cancer cell metastasis. To determine whether OME would affect the cell-
cell adherence behavior of MDA-MB 231, cell aggregation assay was 
conducted on a control and OME-treated cells. We found that OME 
significantly increased the ability of MDA-MB-231 cells to form cell 
aggregates visible and as early as 30 minutes post-treatment (fig. 53). It is 
known that loss of E-cadherin expression promotes tumor progression 
and metastasis while its overexpression prevents the invasion of tumor 
cells. We therefore sought to examine the expression of E-cadherin in 
MDA-MB-231 cells in response to OME exposure. We first examined the 
protein level of E-cadherin in MDA-MB-231 cells treated with and without 
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OME. As shown in figure 54, OME induced a significant increase of E-
cadherin protein in a concentration-dependent manner. This increase in E-
cadherin expression was further confirmed by immunofluorescence 
staining (fig. 55). The expression of E-cadherin was mostly detected at 
cells junctions.  
Next we determined whether the effect of OME on E-cadherin 
expression was mediated through transcriptional regulation.  Toward this, 
transcription activity was measured in cells transfected with a Luciferase 
Reporter gene containing E-cadherin promoter and treated with and 
without OME. As shown in figure 56, OME induced a concentration-
dependent increase in the luciferase activity, thus indicating that OME 
positively regulates the expression of E-cadherin at the transcriptional 
level. Taken together, the data clearly show that E-cadherin is upregulated 
by OME and further suggests that the expression of this protein could 
account for the inhibition of cellular migration and invasion.  
 
Figure 53. Photograph Under Phase-Contrast Microscope (x100 
Magnification) Showing Aggregated Cells After OME Treatment. 
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Figure 54. Western Blot Analysis of E-cadherin Expression in OME 
Treated MD-MB-231 Cells. 
 
 
 
Figure  55. Immunofluorescence Staining for E.cadherin in OME Treated 
MDA-MB 231Cells. DAPI was used as a nuclear stain. 
 
 616 
 
 
Figure  56. E. cadherin Promoter Activity Following Transfection with A 
Luciferase Reporter Gene Containing E-cadherin Promoter in MDA-MB-
231 Cells. 
   
3.22 O.  majorana Inhibited Invasive Capacity of MDA-MB-231 Cells   
Next, we examined the invasive potential of MDA-MB-231 cells in 
the Matrigel-coated Boyden Chamber in the absence, or presence, of 150 
µg/mL OME. The number of OME-treated cells that has passed through 
the Matrigel coated membrane was markedly reduced by 55% (fig. 57, 
and 58), indicating that OME can inhibit the invasive ability of the MDA-
MB-231 cells.  
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Figure  57. O. majorana Inhibited the Invasive Activity of MDA-MB-231 
Cells. 
 
 
Figure 58. Quantification of Invaded MDA-MB-231 into the Matrigel. 
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3.23 O. majorana Suppressed the Expression and the Activity of 
MMP-2 and MMP-9 and downregulated uPAR in MDA-MB-231 Cells 
Matrix metalloproteinases (MMP) -2 and -9, among other MMPs, 
are known to play an important role in breast cancer cell invasion and 
metastasis. To test whether O. majorana inhibits breast cancer cell 
invasion by affecting the expression of MMP-2 and MMP-9, we decided to 
examine the expression levels of MMP-2 and MMP-9 proteins in a 
conditioned medium using OME-treated MDA-MB-231 cells. The protein 
level of MMP-2 and MMP-9 (fig. 59) were found to be significantly reduced 
in response to OME treatment. RT-PCR analysis also revealed that the 
MMP-2 and MMP-9 mRNA level was reduced in MDA-MB-231 cells upon 
treatment with OME (fig. 60) indicating that OME can inhibit the 
transcription of MMP-2 and MMP-9 genes in these cells. 
 
Figure   59. Effects of OME on the Secretions of MMP-2 and MMP-
9 in the Collected Conditioned Medium of OME Treated MDA-MB-
231 Cells. 
  
 612 
 
 
 
Figure  60. RT-PCR Analysis of the mRNA Levels of MMP-2 and MMP-9 
in MDA-MB-231 Cells Treated with OME for 24 Hours. GAPDH was used 
as an internal control. 
 
Then, we decided to examine the effect of OME on the activity of 
MMP-2 and MMP-9. MDA-MB-231 cells were treated with 150 and 300 
µg/mL OME for 24 hours in serum free DMEM, the media was collected, 
concentrated and tested for MMP2 and MMP-9 activity by using gelatin 
zymography. As shown in figure 61, MMP-2 and MMP-9 activities were 
significantly reduced in response to OME treatment. Altogether, our 
results showed that OME significantly inhibits both, the expression and the 
activities of MMP-2 and MMP-9.  
The Urokinase Plasminogen Activator (uPA) and its receptor 
(uPAR) were also shown to play a crucial role in breast cancer cell 
invasion and metastasis. Therefore, we examined whether OME also 
alters the expression of uPAR. Western blot analysis clearly shows that 
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the expression level of uPAR decreased markedly in OME-treated MDA-
MB-231 cells (fig. 62).  
 
Figure   61. Activities of MMP-2 and MMP-9 in OME Treated MDA-MB 
231 Cells. 
 
 
 
 
Figure  62. Western Blot Analysis of uPAR Expression in OME Treated 
MD-MB-231 Cells. β-actin is used as loading control. 
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3.24 O. majorana Decreased Adhesion of MBA-MB-231 to HUVEC and 
downregulated the Expression of ICAM-1 in Breast Cancer Cells  
The attachment of tumor cells to endothelial blood vessels is also a 
crucial event in the process of metastasis. The effect of OME on MDA-
MB-231 cell adhesion to TNF-α stimulated HUVECs was then investigated 
by co-incubating both cell types for 1 hour with, and without various 
concentrations of OME. Figure 24A shows that OME significantly inhibited 
the adhesion of MDA-MB-231 cells to HUVECs in a concentration-
dependent manner.   
Also, because the intercellular adhesion molecule (ICAM)-1, has 
been shown to play an important role in the adhesion of cancer cells to 
endothelial cells and therefore in metastasis, we sought to examine 
whether OME affects the expression of this adhesion molecule in MDA-
MB-231 cells. Toward this aim, cells were treated with various 
concentrations of OME and the protein level of the ICAM-1 was 
determined by Western blotting. As it is shown in figure 64, the level of 
ICAM-1 protein decreased in a concentration-dependent manner in OME-
treated MDA-MB-231 cells. Taken together, our results suggest that OME 
exerts an inhibitory effect on the adhesion of MDA-MB-231 cells to 
HUVEC and that this effect is associated with downregulation of ICAM-1 
protein. 
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Figure 63. Inhibition of Adhesion of MDA-MB-231 Cells to HUVEC by O. 
majorana. 
 
 
Figure  64. Western Blot Analysis of ICAM-1 Expression in OME Treated 
MD-MB-231 Cells. β-actin is used as loading control. 
 
3.25 O. majorana Inhibited Transendothelial Migration of MDA-MB-
231 Through TNF-α-Stimulated HUVECs 
Since the migration of tumor cells through the vascular endothelium 
is another crucial event in the metastasis process, we used the 
Transendothelial Migration Assay to investigate the effect of OME on the 
ability of MDA-MB-231 cells to migrate across a monolayer of endothelial 
(HUVEC) cells.  As seen in figure 65, the transendothelial migration of 
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OME treatment through the monolayer of HUVEC was significantly 
reduced by the treatment with OME in a concentration-dependent manner.  
 
Figure  65. O. majorana Inhibited Migration of MDA-MB-231 Cells A cross 
Monolayer of TNF- α Activated HUVECs. 
  
3.26 O. majorana Suppressed VEGF Production in HUVECs and 
MDA-MB-231 Cells  
Tumor growth and metastasis critically depend on angiogenesis. 
VEGF, a pro-angiogenic growth factor, has been shown to play an 
important role in this process. Thus, we investigated the effect of OME on 
the production of VEGF by both the MDA-MB-231 and endothelial cells 
(HUVEC) with, and without, the presence of TNF-α. We first examined the 
effect of OME on basal expression levels of VEGF in MDA-MB-231 cells. 
Cells were grown with various concentrations of OME, the conditioned 
medium was collected and the level of VEGF measured by ELISA. Data 
shown in Figure 66 revealed that treatment with 300 and 450 µg/mL OME 
for 24 hours markedly reduced the secretion of VEGF by MDA-MB-231 
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cells. VEGF levels dropped from 1300 pg/mL in the control to 800 and 400 
pg/mL respectively.  To further confirm the inhibition of VEGF production 
in breast cancer cells, we measured the level of VEGF in MDA-MB-231 
cells that were first treated with various concentration of OME and then 
stimulated with TNF-α. As shown in figure 67, the production of VEGF was 
enhanced in TNF-α - stimulated (2600 pg/mL) compared to vehicle-treated 
(1500 pg/mL) MDA-MB-231 cells. However, VEGF production was 
significantly reduced in a concentration-dependent manner by OME (fig. 
67). Next, we examined VEGF production in HUVECs. As expected, a 
HUVEC cultured in the absence of TNF-α produced low level of VEGF (20 
pg/mL), while in the presence of TNF-α, VEGF production increased to 
approximately 120 pg/mL (fig. 68). Exposure of HUVEC to OME also led 
to a concentration-dependent suppression of VEGF production (fig. 68).  
 
 
Figure  66. Quantification of Basal Level of VEGF Secretion in 
Conditioned Medium from Vehicle or OME Treated MDA-MB-231 Cells. 
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Figure 67. Quantification of VEGF Secretion in TNF-α Induced MDA-MB-
231 Cells Cultured in Presence of Vehicle or Indicated Concentrations of 
OME. 
 
 
Figure  68. Quantification of VEGF Secretion in TNF-α Induced HUVECs 
Cultured in Presence of Vehicle or Indicated Concentrations of OME. 
. 
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3.27 O. majorana Inhibited Phosphorylation of IκB; Downregulated 
Nuclear Level of NFB 
The NFB signaling pathway is known to regulate the expression of 
various genes involved in tumor cell invasion. To investigate the effect of 
OME on the activation of the NFB signaling pathway, we first examined, 
by Western blotting, the phosphorylation status of IB in OME-treated 
MDA-MB-231 cells. We found that OME drastically inhibited the 
phosphorylation of IB (fig. 69). Moreover, we found that OME reduced 
the level of nuclear NFB remarkably (fig. 70). Taken together, the data 
clearly indicates the OME exerts its effect at least partly through an 
inhibition of the NFB signaling pathway. 
 
 
 
Figure 69. Western Blot Analysis of the Phosphorylation Status of IκBα. 
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Figure 70. Western Blot Analysis of the Nuclear p65 (NFB). β-actin 
(loading control) proteins. 
 
3.28 O. majorana Reduced Nitric Oxide (NO) production in MDA-MB-
231 Cells 
Nitric oxide (NO) signaling has also been shown to promote breast 
tumor growth and metastasis by altering the expression of genes 
implicated in cellular migration, invasion and angiogenesis [164-166]. To 
test whether OME could affect the level of NO, the amount of nitrate/nitrite 
production was determined by ELISA in vehicle and OME-treated MDA-
MB-231 cells. Results shown in figure 71 clearly show that OME 
decreased NO production in a concentration-dependent manner in MDA-
MB-231 cells, thus suggesting that OME could also exert its anti-
metastatic effect by modulating the level of NO in breast cancer cells.  
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Figure 71. Quantification of NO Levels in OME Treated MDA-MB-231 
Cells. 
 
3.29 O. majorana Inhibited Tumor Growth and Metastasis in Chick 
Embryo Tumor Growth and Metastasis Assay 
To further confirm the in vitro anti-breast cancer activities of O. 
majorana, we decided to investigate its effect on tumor growth in vivo by 
using the chick embryo model. MDA-MB-231 cells were grafted on the 
chorioallantoic membrane (CAM) and formed tumors were treated every 
48 hours with vehicle, colchicine (2 µM) or increased concentrations of 
OME (300 and 450 µg/mL). At E19, tumors were recovered from the 
upper CAM and weighed. As it is shown in figure 72 and 73, OME 
significantly inhibited tumor growth compared with the control treatment. In 
fact, concentrations of 300 and 450 µg/mL OME led to reduced tumor 
growth by 55 and 60% respectively. A similar effect (65% inhibition) was 
obtained with 2 µM colchicine. Toxicity was evaluated by comparing the 
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number of dead embryos in OME-treated and control (vehicle-and 
colchicine-treated) embryos. We found that OME showed no toxicity to the 
embryo (data not shown). 
We next assessed for the ability of OME to inhibit metastasis by 
counting the number of nodules in the lower CAM in vehicle, colchicine 
and OME treated tumors. An average of 6.6 nodules were counted in the 
lower CAM of vehicle-treated chick embryo, while an average of only 1.1 
nodules were counted in 300 and 450 µg/mL OME-treated embryos (fig. 
74). The data clearly demonstrates that OME could efficiently inhibit 
breast tumor growth and metastasis in vivo. 
 
Figure  72. Anti-tumor Growth of O. majorana on Breast Tumor in a 
Chick Embryo Chorioallantoic Membrane Model System. 
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Figure 73. Quantification of Tumor Weight in Vehicle, Colchicine and 
Indicated Concentrations of OME Treated Chick Embryo. 
 
 
Figure 74. Anti-Metastatic Effect of O. majorana. Quantification of Nodules 
Observed in the Lower CAM of Chick Embryo Treated with Vehicle, 
Colchicine or OME. 
 
  
 665 
 
DISCUSSION 
Common cancer treatment drugs aim at inhibiting cell cycle 
progression and at inducing cell death and apoptosis. Cancer 
chemoprevention through these two events (cell cycle arrest and 
apoptosis) has been reported for several natural compounds [21, 167-70]. 
In the present study, we have shown that extract of an ethanolic 
fraction of Origanum majorana inhibited the proliferation of mutant p53 
triple negative breast cancer (TNBC) cell line, MDA-MB-231. We have 
also demonstrated that OME induces a differential concentration-
dependent effect on these cells. OME induces a cell cycle arrest at the 
G2/M phase and more precisely a mitotic arrest at low concentrations. 
This finding is supported by a body of evidence: (i) an increase in the level 
of p(ser10)H3, a mitotic marker, and (ii) an increase of cyclin B1 protein 
level, whose upregulation was reported in several mitotically arrested 
cells. We have also shown that cell cycle arrest correlates with an 
upregulation of the CDK inhibitor p21 and the anti-apoptotic protein, 
survivin. At high concentrations, however, OME induced a massive 
apoptosis demonstrated by a dramatic increase in the sub-G1 population. 
We have demonstrated that OME exerts its apoptotic effect by activating 
the cell death extrinsic pathway, at least partially, via the activation of 
TNF-α. We have also shown that OME-induced apoptosis is mediated by 
an increase in DNA damage, revealed by an upregulation of γH2AX, 
severe depletion of the mutant p53 and survivin proteins from the treated 
cells. 
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The process of apoptosis can be induced either by the extrinsic 
pathway which involves signaling from death receptors at the cell surface 
or by the intrinsic mitochondria-mediated pathway [171]. Activation of the 
death receptor-mediated apoptosis requires the interaction of ligands such 
as TNF-α and Fas with their transmembrane receptors [172]. The ligand-
receptor interaction leads to the activation of the effector Caspase 8, 
which in turn activates the effector Caspase 3 directly and/or through 
mitochondria [173]. The mitochondria-mediated apoptosis pathway is 
associated with permeabilization of the mitochondria outer membrane, 
reduced mitochondrial membrane potential (Δψm), change in expression 
of the anti-apoptotic Bcl2 family members, such as Bcl2 and Bcl-XL and 
the pro-apoptotic members such as Bax and Bak lead to the formation of 
apoptosome, activation of Caspase 9 and consequently activation of 
caspase 3 [174]. Intrinsic- and extrinsic-pathways activated Caspase 3, 
cleave PARP, thus resulting in apoptosis [175]. In the present study, we 
showed that OME induced a TNF-α-mediated extrinsic apoptotic pathway. 
A TNF-α receptor was activated at 24 hours and induced downstream 
signaling such as Caspase 8, caspase 3, and PARP cleavage. On the 
other hand, OME did not induce mitochondria-mediated apoptotic pathway 
since no change in the BAX/Bcl2 ratio or activation of Caspase 9 were 
detected. We suggest that OME induces apoptosis solely through a TNF-α 
activated signal pathway in MDA-MB-231 cells. 
Studies have reported that DNA damage is one of the molecular 
events associated with cell cycle arrest and apoptosis. Indeed, many anti-
cancer drugs have been shown to induce DNA damage [176] [177]. 
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Moreover, cancer cells are reported to be more susceptible than normal 
cells to DNA damaging agents [178], therefore there is a growing interest 
in dietary phytochemicals that possess DNA-damaging activity. In the 
present study we showed that OME elicited DNA damage measured by an 
increase in a concentration-dependent manner of the marker of DNA 
damage, γ-H2AX, after treatment with OME for 6 or 24 hours. The 
differential response to the different concentrations of OME (G2/M arrest 
and/or apoptosis), may be partially mediated by the extent of DNA 
damage that occurs within the genome. Low levels of DNA damage may 
trigger recruitment of DNA repair complexes, expression of anti-apoptotic 
and survival proteins leading to arrested cell cycle until the genotoxic 
lesions are repaired. In this case, survival proteins such as survivin get 
activated in order to maintain the viability of G2/M arrested cells. On the 
other hand, when genomes are overwhelmed by DNA damage, cells are 
eliminated by apoptosis [179, 180]. In this study, we have found that high 
concentrations of OME triggered high level of DNA damage to the 
genome, causing cell to enter apoptosis. Our data suggest that Origanum 
majorana possess a genotoxic effect on MDA-MB-231 cells. At this stage, 
the mechanism(s) by which OME induces DNA damage remain(s) 
unknown, and certainly deserves further study. 
Inhibitor of apoptosis proteins (IAPs), which includes survivin, 
represents a family of anti-apoptotic proteins that bind and inactivate 
active Caspase 3/7 [146, 147] and Caspase 9 [148] and can modulate cell 
division and cell cycle progression [149]. 
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Interestingly, survivin has no effect on Caspase 8 activity. Survivin has 
been shown to be highly expressed in most cancers, where it functions as 
an inhibitor of apoptosis. In breast cancer, overexpressed survivin was 
shown to protect cells against apoptosis induced by chemotherapeutic 
agents, such as etoposide [146]. Based on these reports, survivin proteins 
represents an attractive target of particular importance in cancer therapy 
at large and in breast cancer therapy in particular. In consideration of the 
recognized role for survivin as a custodian of cancer cell survival, our 
results suggest that OME might exert its cytotoxic anti-cancer effects, at 
least partly via the downregulation of survivin. In our study, we have 
shown that survivin expression is differentially regulated in a 
concentration-dependent manner by OME. Lower concentrations of OME 
induced an upregulation of survivin which causes cells to arrest the cell 
division and to resist apoptosis by inhibiting the cell death program. In 
fact, we showed that in these arrested cells, PARP cleavage was not 
detected despite the activation of Caspase 3/7. This effect might be 
mediated by the inhibition of active 3/7 by the upregulated survivin. 
Survivn function could also account for the mitotic arrest induced by OME. 
In fact, survivin, has also been shown to be required for mitotic arrest of 
HeLa cells induced by the anti-cancer drug UCN-01 [181]. 
The tumor suppressor protein, p53 is found to be mutated in about 
50% of human cancers [150]. Mutant p53 is reported to play a key role in 
cancer cells resistance to certain anti-cancer drugs and thus is considered 
as a potential cancer-specific target for pharmacologic interventions [182], 
[183]. Studies have shown that inhibition of mutant p53 by RNA 
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interference sensitizes cancer cell to cell death by chemotherapeutic 
agents [184]. Wang et al. 2011, showed that the naturally occurring 
isothiocyanate (ITC) phenetyl isothiocyanate (PEITC), derived from the 
watercress plant, and the synthetic ITC, 2,2-di phenetyl isothiocyanate 
selectively deplete mutant, but not the wild-type p53, and induce 
apoptosis in many cancer cells, including MDA-MB-231 breast cancer 
cells [185]. Here, we showed that OME led to a dramatic decrease in the 
mutant p53 level in MDA-MB-231 cells. As such, mutant p53 depletion 
may be an important target for chemoprevention and therapy by O. 
majorana for TNBC. 
Increase in the expression of the cyclin-dependent kinase inhibitor, 
p21 has been shown to augment G2/M arrest via a p53-independent 
mechanism in human breast cancer [186]. In most cases, growth arrest 
was found to be associated with apoptosis. In this study, we showed that 
low concentrations of OME treatment led to G2/M arrest without significant 
increase in cell death after 24 hours treatment. Histone hyperacetylation 
has been demonstrated to be directly linked to the upregulation of p21 and 
this activation can also occur independently of p53 [187]. Moreover, 
histone hyperacetylation was also shown to be associated with growth 
suppression and apoptosis. Our data showed that OME induced histone 
H3 and H4 hyperacetylation in MDA-MB-231 cells, suggesting that the 
anti-breast cancer effects of OME were at least partly mediated by 
Histone H3 and H4 hyperacetylation by regulating the expression of the 
genes controlling these two events. The mechanism by which OME 
induces histone hyperacetylation might involve a Histone Deacetylase 
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Inhibitor (HDI) activity. Interestingly, the plant, O. majorana, contains 
luteolin, a dietary flavonoid with HDI activity [98]. In fact, luteolin was able 
to decrease the viability of lung, colon, liver and breast cancer cells and 
induce hyperacetylation of histone H3 and H4 [188]. In light of this, we 
conclude that the Histone hyperacetylation induced by OME is involved 
with the HDI activity of luteolin. We are currently undertaking further 
investigations to better understand the mechanism(s) by which OME 
induces Histone hyperacetylation. 
In conclusion, our data is consistent with the model shown in figure 
75 which shows the concentration-dependent differential effect of O. 
majorana extract on mutant p53, triple negative MDA-MB-231 cells. At low 
concentrations, OME induced a mitotic arrest associated with low level of 
DNA damage (75, thin arrow), upregulation of the CDK inhibitor p21 and 
the inhibitor of apoptosis, survivin. We believe that these events along 
with other yet to be identified events contribute to the cell cycle arrest. In 
addition we also propose that, at these concentrations, survivn is also 
implicated in the blockage of the TNF-mediated apoptosis pathway, by 
directly inhibiting the activity of the active Caspase 3. On the other hand, 
high concentrations, OME induce massive apoptosis via the activation of 
the TNF-α extrinsic pathway which is associated with high level of DNA 
damage (fig. 75, thick arrow) and almost complete depletion of the mutant 
p53 and surviving proteins from these cells. Our findings provide the first 
instance of a potential role for OME as an anti-breast cancer agent in vitro 
which certainly deserves more attention and further exploration to identify 
novel compounds for breast cancer. 
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Figure 75. Proposed Mechanisms of Action of O. majorana on MDA-MB-
231 Cells.  
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Tumor invasion and metastasis is a multistep process involving cell 
adhesion, proteolytic degradation and migration through the ECM and 
angiogenesis. Common cancer treatment drugs aim at blocking cell cycle 
progression, inducing cell death and/or inhibiting tumor migration and 
invasion. Cancer chemoprevention through these events has been 
reported for several natural compounds [21] [167-170].  Nowadays, there 
is a growing interest in combination therapy using multiple anti-cancer 
drugs affecting several targets/pathways.  Herein, we demonstrate for the 
first time that O. majorana, at non-cytotoxic concentrations, possesses 
potent anti-metastatic properties against the highly invasive triple negative 
breast cancer cell line, MDA-MB-231. In fact, O. majorana efficiently 
inhibited the migratory abilities and induced homotypic aggregation of 
MDA-MB-231 cells, associated with an upregulation of E-cadherin 
expression. We also showed that O. majorana not only decreased the 
adhesion of MDA-MB-231 to HUVECs as well as their transendothelial 
migration, but also inhibited the secretion of the pro-angiogenic factor 
VEGF from both endothelial and breast cancer cells. In addition we 
demonstrate that O. majorana suppressed the expression and the 
activities of MMP-2 and MMP-9 and downregulated the expression of 
uPAR and ICAM-1. O. majorana also blocked IB-α/NFB and reduced 
Nitric Oxide (NO) production, both signaling events involved in cancer cell 
invasion. Moreover, we demonstrated that O. majorana significantly 
inhibited tumor growth and metastasis in vivo in a chick tumor growth 
assay. 
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It is well known that disruption of cell-cell adhesion during cancer 
progression is the initial stage required for the acquisition of invasive 
properties. Decreased cell-cell adhesion in cancer cells is often 
characterized by diminished expression of E-cadherin. Indeed, E-
cadherin, a calcium-dependent, cell adhesion molecule, is considered as 
a tumor suppressor in breast cancer [189]. A decrease in E-cadherin 
expression is a critical and necessary event required in the disruption of 
cell-cell adhesion and thus for the acquisition of invasive phenotype of 
various tumors including breast cancer. In fact, downregulation or loss of 
E-cadherin during cancer progression is associated with aggressive 
behavior by the tumor and a poor prognosis for the patient [190]. 
Conversely, expression of E-cadherin can lead to a reduced progression 
and invasion of breast cancer cells [191]. In the present study, we 
demonstrated that O. majorana inhibited cell migration and promoted 
homotypic cell-cell aggregation and induced overexpression of E-cadherin 
in the MDA-MB-231 cells.  We postulate that O. majorana exerts its anti-
migratory effect on breast cancer cells, at least partly, through reactivation 
of the expression of E-cadherin gene. In fact we showed that OME was 
able to induce transactivation of E-cadherin promoter in transfected cells 
(Fig. 3D). Induction of E-cadherin expression promotes then homotypic 
aggregation of OME-treated MDA-MB-231 cells. Thus, E-cadherin 
overexpression is one of possible mechanism by which O. majorana 
exerts its anti-invasive effect on the MDA-MB-231 cells. 
Recent studies showed that treatment with histone deacetylase 
inhibitors such as SAHA and trichostatin A strongly inhibited the migration 
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and invasion of breast and prostate cancer cells and caused an 
upregulation of E-cadherin [192, 193]. Histone Deacetylase (HDAC) 
Inhibitors, promising anticancer agents, have been shown to mediate their 
effects by activating the transcription of specific genes through histone 
hyperacetylation. Interestingly, we have recently shown that O. majorana 
induces hyperacetylation of Histone H3 and H4 at non-cytotoxic 
concentrations. Moreover, O. majorana has been shown to contain 
luteolin [98], a dietary flavonoid with Histone Deacetylase Inhibitor activity, 
which was also shown to inhibit the invasive potential of MDA-MB-231 
cells [188].  
Based on these findings, we can suggest that one possible 
mechanism by which O. majorana exerts its anti-migratory and anti-
metastatic effects on MDA-MB-231 involves an upregulation of E-cadherin 
gene expression through Histone hyperacetylation. However, at this 
stage, we cannot rule out the involvement of other mechanism(s) being 
involved in this regulation. Further investigation will be needed to decipher 
the exact mechanism by which O. majorana exert its effect on E-cadherin 
expression. 
The dissemination of cancer cells from the primary tumor is another 
crucial event in the process of cancer invasion and metastasis, which 
involves the degradation of the ECM and the components of the basement 
membrane through proteases. Of these proteases, MMPs such as MMP-
2, MMP-9 and the uPA are thought to play a key role in cancer cell 
invasion and metastasis [194, 195]. It has been shown that increasing 
expression of MMPs in breast cancer cells correlates with increasing 
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aggressiveness of breast cancer cell growth and metastatic potential 
[196]. Therefore, inhibiting the activity or the expression of these 
proteases can be considered as a potential therapeutic target against 
breast cancer.  Interestingly, here we clearly demonstrate that O. 
majorana exerts its anti-invasive affect against MDA-MB-231 cells by 
significantly downregulating the expression of uPAR, MMP-2 and MMP-9 
and decreasing the activity of these two proteases and consequently 
reducing ECM degradation.  
The ability of tumor cells to metastasize also largely depends on 
their ability to adhere and transmigrate though endothelial cells. Cancer 
cell-endothelial cell interaction is mediated by various adhesive molecules 
such as intracellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule-1 (VCAM-1) and E- selectin [197]. Studies have shown 
that the level of ICAM-1 protein expression on the cell surface positively 
correlated with metastatic potential of several breast cancer cell lines [16]. 
Moreover, down regulation of ICAM-1 at the protein and mRNA levels 
strongly inhibited human breast cancer cell invasion [16]. Tanshimone I, a 
natural compound derived from medicinal plant, Salvia miltiorrhiza, 
efficiently inhibited the adhesion of MDA-MB-231 cells to HUVECs by 
down regulating the expression of ICAM-1 and VCAM-1 [198]. Recent 
studies have revealed that ICAM-1 expression is associated with a more 
aggressive breast tumor phenotype [199]. Based on these findings, ICAM-
1 represents a potential target in breast cancer treatment. Our study 
revealed that O. majorana was able to reduce the expression levels of 
ICAM-1 proteins in MDA-MB-231 cells and blocked their adhesion to the 
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human vascular endothelial cells (HUVECs).  Hence, we propose that 
downregulation of ICAM-1 expression could be one mechanism by which 
O. majorana blocks MDA-MB-231 cells capability to adhere to HUVECs 
and consequently prevents their metastasis.  
Angiogenesis, a process by which new blood vessels form, is 
crucial for tumor growth and metastasis. Blockade of angiogenesis can 
inhibit both tumor growth and metastasis [200]. Thus inhibition of 
angiogenesis can be considered as a promising strategy in cancer therapy 
[201, 202]. One possible way to block angiogenesis is to target pro-
angiogenic factors secreted by tumor cells. VEGF is the major pro-
angiogenic protein expressed in 60% of breast cancer patients at the time 
of first diagnosis [203]. Interestingly, we found that O. majorana 
significantly reduced the production of VEGF in both HUVECs and MDA-
MB-231 cells, suggesting that OME not only inhibits breast cancer cell 
invasion, but could also block angiogenesis.  
The NFB signaling pathway is known to regulate the expression of 
various genes involved in the process of tumor metastasis. Elevated 
levels of NFB are frequently detected in breast cancer cells. Studies 
showed that inhibition of NFB activity could suppress metastasis in 
breast cancer cells. In fact, studies showed that inactivation of NFB in 
MDA-MB-231 breast cancer cells inhibit the expression of many 
downstream target genes involved in tumor metastasis such as MMP-2 
[196], MMP-9 [26, 204, 205],  VEGF [205], ICAM-1 [26] and uPAR [26]. 
The phosphorylation of IB, by the IKKβ subunit of the IKK serine kinase 
complex, is a crucial step in the activation of NFB.  
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In fact, phosphorylation of IB triggers its polyubiquitination and 
proteasome-mediated degradation with consequent NFB nuclear 
localization [206]. Nuclear NFB can then upregulate the transcription of 
its target genes. Therefore, one way to inactivate the activated NFB 
signaling in cancer cells is to block the phosphorylation of Ib by 
inactivating the IKK complex. Interestingly, in the present work, we 
demonstrated that O. majorana inhibited the phosphorylation of IB and 
reduced the protein level of nuclear NFB suggesting that O. majorana 
may negatively regulate the activity of NFB possibly by affecting the 
activity of the IKK complex.  It is worth mentioning that O. majorana 
significantly reduced the expression of several NFB downstream target 
genes (MMP-2, MMP-9, uPAR, ICAM-1 and VEGF) involved in tumor 
metastasis. It appears that the inhibitory effect on NFB could account for 
the anti-metastatic effects of O. majorana.  
Nitric Oxide (NO), synthesized by several nitric oxide synthases 
(NOSs), nNOS/NOS-1, iNOS/NOS2 and eNOS/NOS3 is a signaling 
molecule that regulates several physiological responses such as 
vasodilatation, cell migration, immune reactions and apoptosis [198]. 
Interestingly, various studies have shown that NO can both promote and 
inhibit tumor progression and metastasis. The pro- or anti-tumorigenic 
activities of NO have been related to the p53 status [166, 207]. It has been 
shown that NO-mediated apoptosis in leukemia cells requires wild-type 
p53 [208]. On the other hand, it has been shown that iNOS/NOS2 
expressing carcinoma cells with mutant p53 have accelerated tumor 
growth and increased VEGF production [209]. NO was shown to promote 
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cancer progression through the activation of oncogenic signaling 
pathways including the extracellular signal-regulated kinases (ERK)1/2, 
phosphoinositide 3-kinases (PI3K)/AKT, and c-Myc [124]. Recent studies 
showed that increased iNOS/NOS2 and consequently NO production, 
predicted poor survival in women with estrogen receptor α–negative (ER-
negative) breast tumors. Moreover, exposure to NO enhanced cell motility 
and invasion of Estrogen Receptor negative ER(-) cells [209]. It appears 
then that discovery of inhibitors targeting NO production may be 
particularly efficacious against ER(-), mutant p53 breast cancer patients. 
In the present study we showed that O. majorana efficiently reduced the 
level of NO production in the MDA-MB-231 in a concentration dependent 
manner, suggesting that O. majorana might exert its anti-metastatic effect, 
at least partly, by modulating the NO production in MDA-MB-231 cells. As 
such, NO production may be an important target for chemoprevention 
and therapy by O. majorana for the ER(-), mutant p53 MDA-MB-231 cells.  
In summary, this study clearly demonstrated, for the first time, that 
O. majorana possesses anti-invasive and anti-metastatic effects against 
highly proliferative and highly invasive human MDA-MB-231 breast cancer 
cell line by modulating the activity and/or the expression of proteins 
regulating the process of cellular migration, adhesion invasion and 
angiogenesis such as E-cadherin, ICAM-1, MMP-2, MMP-9, uPAR and 
VEGF, at least partly, through inhibition of the NFB and NO signaling 
pathways. Our results also showed that O. majorana inhibited tumor 
growth and metastasis in an in vivo tumor growth assay. Thus, our current 
study identifies Origanum majorana as a promising chemopreventive and 
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therapeutic candidate that inhibits breast cancer growth and metastasis by 
modulating the expression and activities of several targets. Nowadays, 
there is a growing interest in combination therapy using multiple anti-
cancer drugs affecting several targets/pathways, thus O. majorana 
certainly merits a lot of attention and further exploration to identify novel 
compounds for breast cancer therapy. 
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GENERAL CONCLUSION 
In conclusion, our study has focused on natural products such as 
plant extracts and natural compounds found in nature and in our diets as 
potential anti-breast cancer agents. We demonstrated that Salinomycin 
induces apoptosis and senescence in breast cancer through upregulation 
of p21, downregulation of survivin and Histone H3 and H4 
hyperacetylation. Further, we provided evidence that Origanum majorana 
attenuates breast cancer cell invasion, migration and tumor growth in vivo, 
at least in part, through inhibiting the NF activation cascade and 
reduction of Nitric Oxide production. In recent years, an increasing 
number of natural products possessing anti-cancer properties have been 
uncovered. Coupled with the elucidation of their anti-cancer mechanisms, 
the exploitation of their use in clinical chemotherapeutic strategies is 
promising. A potential advantage of phytochemicals and other compounds 
derived from natural products is that they may act through multiple cell 
signaling pathways and reduce the development of resistance by cancer 
cells. Thus, natural products and naturally occurring phytochemicals are 
indeed worthy of further development as anti-cancer and anti-metastatic 
agents for clinical use. 
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